Stephen L. Reitman, M.D.; Decision and Order, 60889-60900 [2011-25227]
Download as PDF
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
Respondent as the primary drug and
money courier strikes at the heart of the
CSA, the very statute that privileged the
Respondent to handle controlled
substances in his medical practice. The
deleterious potential effect that these
drugs can have on the human body, the
peril in which they put human life
when indiscriminately ingested by
willing abusers, and the sheer volume
by which the Respondent was caught
delivering them cannot be overstated.
The reckless danger that the
Respondent’s course of action posed to
the public health and safety of his wife,
at a minimum, and possibly even the
surrounding area and community where
the Burning Man Festival was to take
place, would not be counterbalanced
even if the Respondent had deemed to
submit evidence of many years of
admirably-conducted medical practice.
The offensiveness of his actions,
including the duty imposed by his
Hippocratic oath to abstain from doing
harm, as well as his lack of candor at his
hearing in minimizing the extent to
which he helped orchestrate this
scheme, all militate strongly in favor of
revocation.
Even if the Respondent’s position
regarding the operative facts were
embraced, it would not change the
outcome of this recommended decision.
The Respondent acknowledged during
his testimony that he (correctly)
suspected that his wife was abusing
illicit drugs based on a readily-available
set of objective facts that he was even
able to catalogue upon request during
his testimony. He acknowledged that he
was paying a $1,000.00 to a man who
made him uneasy at the request of his
(likely drug-abusing) spouse. The
Respondent even conceded that any
reasonable person would have realized
that there were illicit drugs in the motor
home he was driving that evening,64 and
that ‘‘[a]ll [he] can claim is to be the
stupidest doctor at the time’’ 65 is (even
if credited) wholly unpersuasive, and
‘‘manifests a degree of irresponsibility
that is incompatible with what DEA
expects of a registrant.’’ Cf. Lynch, 75 FR
at 78753 (registrant’s position that it was
acceptable for him to prescribe
controlled substances in the face of
known and obvious diversion risks on
the theory that he is not a lawyer or
police agent characterized as
‘‘manifest[ing] a degree of
irresponsibility that is incompatible
with what DEA expects of a registrant’’).
Reduced to its essence, the Respondent
seeks relief from his actions and
convictions by a claim that he
64 Tr.
65 Tr.
337.
332.
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
stubbornly refused to acknowledge what
his trained eyes and ears informed him
of: that he was giving money to a drug
dealer and receiving illicit drugs for his
wife that were packaged as if for sale
and driving those drugs to an art festival
in the Nevada desert. The Respondent’s
odd theory that turning a blind eye to
circumstances that required him to
refrain from actions that were repugnant
to his responsibilities as a registrant,
and whistling past the graveyard of
what was obviously a drug transaction
where he was playing an integral role,
is not a persuasive argument in favor of
continuing to entrust him with the
responsibilities of a DEA registrant.
Cf. Holloway Distrib., 72 FR 42118,
42124 (2007) (in the context of a List I
distributer, a policy of ‘‘see no evil, hear
no evil’’ is fundamentally inconsistent
with the obligations of a DEA
registrant). In short, his efforts to
convince DEA that he is ‘‘the stupidest
doctor,’’ 66 even if successful, would
hardly have inspired sufficient
confidence in his ability to continue to
execute the responsibilities attendant
upon a registrant to fairly merit his
continued exercise of that privilege.
Accordingly, the Respondent’s
Certificate of Registration should be
Revoked and any pending applications
for renewal should be Denied.
Dated: January 24, 2011.
John J. Mulrooney, II,
U.S. Administrative Law Judge.
[FR Doc. 2011–25224 Filed 9–29–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 09–65]
Stephen L. Reitman, M.D.; Decision
and Order
On July 20, 2010, Administrative Law
Judge Gail A. Randall issued the
attached recommended decision.1
Neither party filed exceptions to the
ALJ’s decision.
Having reviewed the entire record, I
have decided to adopt the ALJ’s rulings,
findings of fact, conclusions of law,2
66 Tr.
332.
citations to the ALJ’s decision are to the slip
opinion as issued by her.
2 The ALJ found that Respondent violated
California law by obtaining controlled substances
from a distributor ‘‘while concealing the fact that
he was dispensing to himself.’’ ALJ at 33 (citing Cal.
Health & Safety Code 11173). The ALJ did not,
however, cite any decisional law holding that
conduct similar to that engaged in by Respondent
violates this provision. See id. Moreover, there is no
evidence establishing that Moore Medical required
1 All
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
60889
and recommended order except as
discussed below. Accordingly, while
Respondent’s registration will be
continued, I conclude that the record
requires that several conditions be
placed on it to adequately protect the
public interest.
At the time of the hearing, the
Medical Board of California (MBC) had
filed an accusation against Respondent.
ALJ at 31. However, the MBC did not
issue a final decision in the matter until
December 20, 2010, which became
effective on January 19, 2011. In re
Stephen Lee Reitman, M.D., Decision at
1 (Cal. Med. Bd. Dec. 20, 2010). I take
official notice of the MBC’s Decision
and the Stipulated Settlement and
Disciplinary Order.3 Therein, the Board
revoked Respondent’s medical license
but stayed the revocation and placed
him on probation for five years subject
to numerous conditions. Stipulated
Settlement, at 4. The conditions
include, inter alia, that Respondent
‘‘maintain a record of all controlled
substances ordered, prescribed,
dispensed, administered, or possessed
by’’ him, that he abstain ‘‘from the
personal use or possession of controlled
substances’’ except as ‘‘to medications
lawfully prescribed to [him] by another
practitioner for a bona fide illness or
condition’’ and that he ‘‘notify the
Board’’ within fifteen calendar days of
receiving any such prescription, and
that he take both a prescribing practices
course and an ethics course. Id. at 4–10.
Most significantly, the Order requires
that Respondent, at his own expense,
‘‘contract with a laboratory or service—
approved in advance by the Board or its
designee—that will conduct random,
unannounced, observed, urine testing a
maximum of four times each month.’’
Id. at 5. Moreover, ‘‘[t]he contract shall
require results of the urine tests to be
transmitted by the laboratory or service
directly to [the] Board or its designee
Respondent to make any disclosure as to his
purpose in purchasing the drugs. Cf. Lovejoy v.
AT&T Corp., 92 Cal.App.4th 85, 96 (2001) (noting
that tort of concealment requires that ‘‘the
defendant must have been under a duty to disclose
the fact to the plaintiff’’). I therefore do not adopt
this finding. However, the evidence does establish
the other violations of the CSA and State law as
discussed by the ALJ.
3 Under the Administrative Procedure Act (APA),
an agency ‘‘may take official notice of facts at any
stage in a proceeding-even in the final decision.’’
U.S. Dept. of Justice, Attorney General’s Manual on
the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). In accordance
with the APA and DEA’s regulations, Respondent
is ‘‘entitled on timely request, to an opportunity to
show to the contrary.’’ 5 U.S.C. 556(e); see also 21
CFR 1316.59(e). Respondent can dispute the facts
of which I take official notice by filing a properly
supported motion for reconsideration within twenty
days of service of this Order, which shall begin on
the date it is mailed.
E:\FR\FM\30SEN1.SGM
30SEN1
mstockstill on DSK4VPTVN1PROD with NOTICES
60890
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
within four hours of the results
becoming available’’ and that
Respondent’s ‘‘[f]ailure to maintain this
laboratory or service during the period
of probation is a violation of [his]
probation.’’ Id. at 5–6. Finally, the Order
provides that it is a violation of
Respondent’s probation if he ‘‘[f]ail[s] to
submit to or comply with the time frame
for submitting to, or fail[s] to complete
the required biological fluid testing.’’ Id.
at 5–6.
In her decision, the ALJ rejected the
Government’s contention that
Respondent’s registration should be
revoked because he has been sober for
only eleven months and that this is an
insufficient period to demonstrate that
he is not likely to relapse. ALJ at 35
(citing Gov. Br. at 9–10). In so ruling,
the ALJ reasoned that ‘‘‘[t]he paramount
issue is not how much time has elapsed
since [the Respondent’s] unlawful
conduct, but rather, whether during that
time [the] Respondent has learned from
past mistakes and has demonstrated that
he would handle controlled substances
properly if entrusted with a DEA
registration.’’’ Id. (quoting Leonardo v.
Lopez, M.D., 54 FR 36915 (1989)).
However, none of the cases which have
invoked this principle involved
circumstances similar to those at issue
here, where, a registrant has abused
controlled substances for seven years
and has demonstrated his sobriety for
only one year. See Lopez, 54 FR 36915;
see also Robert L. Dougherty, M.D., 76
FR 16823 (2011); Robert A. Leslie, M.D.,
64 FR 25908 (1999); Mary M. Miller,
M.D., 63 FR 71157 (1998); John Porter
Richards, D.O., 61 FR 13878 (1996);
James W. Shore, M.D., 61 FR 6262
(1996).
That being said, I agree with the ALJ’s
findings that Respondent has accepted
responsibility for his misconduct and
that he has undertaken substantial
efforts at rehabilitation. Indeed, even the
Government acknowledges that
Respondent had taken ‘‘various and
comprehensive steps * * * toward
rehabilitation’’ and that his efforts were
‘‘entered into voluntarily, which no
doubt demonstrates a commitment to
staying clean and sober.’’ Gov. Br. at 9.
However, as the Government noted in
its brief, according to the evidence
adduced at the hearing, under the terms
of Respondent’s contract with his
treatment program, the program is not
obligated to report any relapse to either
the MBC or this Agency.4 Id; see also Tr.
91. Given the limited time for which
Respondent has demonstrated his
sobriety (on the record of the hearing),
4 Respondent
did not introduce into evidence a
copy of his treatment contract.
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
such an arrangement is manifestly
inadequate to support the continuation
of a registration. Thus, I am not
persuaded by the ALJ’s reasoning that
‘‘under the particular circumstances of
this case, nine months is not such a
short recovery period that it should
serve as grounds for revocation.’’ ALJ at
36.
However, as found above, subsequent
to the closing of the record, Respondent
entered into a Stipulated Settlement and
Disciplinary Order with the MBC which
provides for random biological fluid
testing and which requires that the
results be reported directly to the MBC.
Moreover, since the record closed,
additional time has passed during
which Respondent has been subject to
random biological fluid testing, and
during this period, no evidence of a
relapse has been presented to this
Office.
These developments, when
considered along with Respondent’s
strong showing as to his acceptance of
responsibility, his efforts at
rehabilitation, as well as the lack of
evidence that he harmed anyone other
than himself or diverted drugs to others,
supports the conclusion that
Respondent’s continued registration
would not ‘‘be inconsistent with the
public interest.’’ 5 21 U.S.C. 823(f).
5 In her discussion of whether Respondent had
accepted responsibility, the ALJ explained that
‘‘[p]ast DEA cases have involved practitioners
whose registrations were either not revoked or their
applications were not denied despite more
reprehensible conduct than [Respondent’s] selfprescribing.’’ ALJ at 37. While I agree that in Judy
L. Henderson, 65 FR 5672 (2000), and Mary
Thomson, M.D., 65 FR 75969 (2000), the registrants
committed acts which are arguably more egregious
than those committed by Respondent, I do not see
any meaningful difference between the conduct
committed by the registrant in Jimmy H. Conway,
Jr., M.D., 64 FR 32271 (1999), and Respondent. As
for her discussion of Robert G. Hallermeier, M.D.,
62 FR 26818 (1997), suffice it to say that were a case
with similar facts presented to me, that individual
would receive a sanction that more appropriately
reflected the grave harm which that registrant
caused the public and the Agency’s interest in
deterring similar misconduct. See Joseph Gaudio,
M.D., 74 FR 10083, 10094 (2009) (citing Southwood
Pharmaceuticals, Inc., 72 FR 36487, 36504 (2007)).
See also Butz v. Glover Livestock Commission Co.,
Inc., 411 U.S. 182, 187–88 (1973).
Finally, the ALJ’s discussion that the applicant in
John Porter Richards, D.O., 61 FR 13878 (1996),
‘‘continued to maintain that he had not committed
the crimes for which he had been convicted,’’ ALJ
at 38, is simply a misreading of that decision. As
the decision makes clear, the text quoted by the ALJ
was a paraphrase of a question posed of the
applicant by the Government on cross-examination.
See 61 FR at 13879 (‘‘When asked on crossexamination whether, consistent with his not guilty
plea, he continued to maintain that he had not
committed the crimes for which he had been
convicted, the Respondent testified, ‘‘I accept my
conviction[.]’’). When the Government then asked
‘‘to what extent he did so,’’ the applicant testified:
‘‘‘In its completeness.’’’ Id. Notably, the decision
contains no further discussion suggesting that the
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
Accordingly, Respondent’s pending
renewal application will be granted.
However, to adequately protect the
public interest, Respondent’s
registration will be subject to the
conditions set forth below, which shall
remain in effect until the same date as
the State’s probation expires. Any
violation of these conditions constitutes
an act which renders his registration
‘‘inconsistent with the public interest,’’
21 U.S.C. 824(a)(4), and subject to
proceedings under that provision.
(1) Respondent’s registration is
restricted to authorizing the prescription
of controlled substances. Respondent
shall not prescribe controlled
substances to himself or any family
members. Respondent is further
prohibited from obtaining controlled
substances from a manufacturer,
distributor, or pharmacy, whether the
controlled substances are obtained by
ordering them from a manufacturer,
distributor, or pharmacy, or provided to
him by a manufacturer, distributor, or
pharmacy as a sample. This condition
does not prohibit Respondent from
obtaining a prescription for a controlled
substance from another practitioner for
a legitimate medical condition and
filling such a prescription at a
pharmacy.
(2) Respondent shall maintain a log of
all controlled substance prescriptions he
issues. Respondent shall provide a copy
of his log each quarter to the local DEA
office within ten business days of the
end of each quarter of the calendar year
(i.e., March 31st; June 30th; September
30th, and December 31st). If Respondent
issues no controlled substance
prescriptions during the quarter, a
report indicating that no prescriptions
were issued must also be filed no later
than ten business days following the
end of the quarter.
(3) Respondent shall consent to
unannounced inspections of his
registered location by DEA personnel
and waives his right to require that
Agency personnel obtain an
Administrative Inspection Warrant prior
to conducting an inspection of his
registered location.
(4) Any violation of the probationary
terms imposed pursuant to the MBC’s
requirement that he contract with a
laboratory or service to provide for
random biological fluid testing shall
constitute grounds for the immediate
suspension of his DEA registration.
applicant acknowledged his conviction but then
denied having committed the crime or claimed that
he was set up.
E:\FR\FM\30SEN1.SGM
30SEN1
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 824(a)(4), as
well as 28 CFR 0.100(b), I order that the
application of Stephen L. Reitman to
renew his DEA Certificate of
Registration be, and it hereby is, granted
subject to the conditions set forth above.
This Order is effective immediately.
Dated: September 20, 2011.
Michele M. Leonhart,
Administrator.
Christine M. Menendez, Esq. for the
Government.
Robert C. Schlein, Esq. for the
Respondent.
Recommended Rulings, Findings of
Fact, Conclusions of Law, and Decision
of the Administrative Law Judge
mstockstill on DSK4VPTVN1PROD with NOTICES
I. Procedural Background
Gail A. Randall, Administrative Law
Judge. The Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration (‘‘DEA’’ or
‘‘Government’’), issued an Order to
Show Cause (‘‘Order’’) dated September
10, 2009, proposing to revoke the DEA
Certificate of Registration Number
AR6012568, of Stephen L. Reitman,
M.D. (‘‘Respondent’’ or ‘‘Dr. Reitman’’),
as a practitioner, pursuant to 21 U.S.C.
824(a)(4), and deny any pending
applications for renewal, modification,
or additional registrations, pursuant to
21 U.S.C. 823(f), because the continued
registration of the Respondent is
inconsistent with the public interest, as
that term is defined in 21 U.S.C.
824(a)(4). [Administrative Law Judge
Exhibit (‘‘ALJ Exh.’’) 1].
On September 25, 2009, the
Respondent, through counsel, filed a
request for a hearing in the abovecaptioned matter. [ALJ Exh. 2].
The hearing was held in San Diego,
California, on April 13–14, 2010. [ALJ
Exh. 4 at 1; Transcript (‘‘Tr.’’) Vol. I–II].
At the hearing, Counsel for the DEA and
Counsel for the Respondent called
witnesses to testify and introduced
documentary evidence. After the
hearing, both parties submitted
Proposed Findings of Fact, Conclusions
of Law and Argument.
II. Issue
The issue in this proceeding is
whether or not the record as a whole
establishes by a preponderance of the
evidence that the Drug Enforcement
Administration should revoke the DEA
Certificate of Registration Number
AR6012568 of Stephen L. Reitman,
M.D., as a practitioner pursuant to 21
U.S.C. 824(a), and deny any pending
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
applications to renew or modify this
registration under 21 U.S.C. 823(f),
because to continue Respondent’s
registration would be inconsistent with
the public interest as that term is used
in 21 U.S.C. 823(f). [ALJ Exh. 3 at 1; Tr.
5].
III. Findings of Fact
I find, by a preponderance of the
evidence, the following facts:
A. Background
1. Respondent is registered with DEA
as a practitioner in Schedules II–V
pursuant to DEA Registration Number
AR6012568. [ALJ Exh. 3 at 1;
Government Exhibit (‘‘Govt. Exh.’’) 1;
Tr. 58].
2. Respondent is licensed as a
physician and surgeon in the State of
California pursuant to License Number
G25924. Respondent’s licensure status
is renewed and current. [ALJ Exh. 3].
3. Dr. Reitman attended the
University of Illinois in Champaign for
undergraduate school. Then he studied
at the University of Illinois Medical
School in Chicago from 1965 to 1969.
Dr. Reitman graduated medical school
in 1969. [Tr. 55]. He next attended the
University of Cincinnati for internship
and residency from about 1969 until
1972. From there, he studied at Ann
Arbor University of Michigan from 1972
until 1974 for a fellowship in
nephrology. In 1974, he and his wife
moved to San Diego where he has been
in practice since that time. He has been
licensed to practice medicine in
California since 1973. [Respondent’s
Exhibit (‘‘Resp. Exh.’’) 5; Tr. 55–56].
4. Dr. Reitman is currently working in
La Mesa, California. His practice
consists mostly of geriatric and internal
medicine treating senior citizens, people
60 or older. He sees maybe 15 to 20
patients per day. [Tr. 57]. In his
practice, he sees many seniors with
chronic pain. He prescribes Vicodin,
codeine, and Darvocet, as well as antianxiety medications and antidepressants. He does not dispense. [Tr.
58–59].
B. DEA Investigation
5. Diversion Investigator Ayoma Rudy
(‘‘Investigator Rudy’’) has been a
diversion investigator with the DEA in
San Diego, California since November 3,
2005. [Tr. 18–19]. Prior to becoming a
diversion investigator, she was a DEA
group assistant in 1996. [Tr. 19]. She
then became an investigative assistant
in approximately 2001. [Id.]. She trained
for three months at Quantico, where she
received specialized training including
how to conduct regulatory, financial,
and criminal investigations and how to
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
60891
write reports, take affidavits, conduct
search warrants, and conduct
interviews. [Tr. 20]. Investigator Rudy is
now responsible for investigating the
illegal diversion of controlled
substances and listed chemicals. She is
the lead investigator of the issues
surrounding the Dr. Reitman case. [Tr.
20–22].
6. Investigator Rudy began
investigating Dr. Reitman on May 28,
2009, when Moore Medical submitted a
controlled substance report to the San
Diego Field Division showing what the
DEA considered to be excessive
purchases of controlled substances by
Dr. Reitman from Moore Medical. [Govt.
Exh. 3, 5; Tr. 23]. A DEA registrant has
a responsibility to inform the DEA of
any excessive purchases or suspicious
orders. [Tr. 26]. Investigator Rudy’s
supervisor, John Partridge, told her to
follow up on these purchases, because
he considered them excessive. [Tr. 26–
27].
7. A Controlled Substance Utilization
Review (‘‘CURES’’) report is generated
by a California Department of Justice
database, which tells an investigator
what the patient filled, what drugs the
patient filled, when, which pharmacies
the patient went to, and how many
doctors the patient saw within the week
or within the day. [Tr. 22].
8. In the case of the report from Moore
Medical, the DEA Certificate of
Registration Number used to order the
controlled substances was AR6012568,
which is Dr. Reitman’s number. [Govt.
Exh. 3; Tr. 25].
9. Dr. Reitman was ordering Butalbital
APAP (acetaminophen) Caffeine with
codeine 6 and APAP 300mg with
codeine 60mg from January 2005
through March 18, 2009. [Govt. Exh. 5;
Tr. 27–8]. APAP with codeine is a
Schedule V controlled substance. [Tr.
28]. Butalbital APAP with Codeine is a
Schedule III controlled substance. [Tr.
28].
10. On July 8, 2009, DEA Diversion
Investigators Ayoma Rudy and Kenneth
Crouch interviewed Dr. Reitman
regarding controlled substances that he
purchased from Moore Medical. [ALJ
Exh. 3 at 2; Tr. 28].
11. At that time, Dr. Reitman invited
them in, asked them to sit down. [Tr.
29]. Investigator Rudy stated that Dr.
Reitman was friendly, cooperative and
forthright. [Tr. 41–42]. He seemed
coherent and rational. [Tr. 42].
12. Dr. Reitman admitted that the
report from Moore Medical was correct.
[Tr. 30]. He admitted to having an
addiction problem. [Tr. 42]. During the
6 The milligrams are not specified for this drug.
[See Govt. Exh. 5].
E:\FR\FM\30SEN1.SGM
30SEN1
mstockstill on DSK4VPTVN1PROD with NOTICES
60892
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
interview, Dr. Reitman stated that he
ordered the substances in question for
his personal use and that he was not
selling the controlled substances or
exchanging them for other services. [ALJ
Exh. 3 at 2; Tr. 30, 32]. Investigator
Rudy said, ‘‘By the third sentence, he
put his head down’’ and said that he
‘‘ordered [the controlled substances] for
personal use.’’ [Tr. 30]. Dr. Reitman
repeatedly stated that he needs help.
[Tr. 32].
13. At that time, Dr. Reitman kept the
controlled substances in a locked
cabinet at his office location, the
contents of which he showed to the two
Diversion Investigators. [ALJ Exh. 3 at 2;
Tr. 31–32]. He opened the cabinet, and
DI Rudy could see about 22 or 23 bottles
of the Butalbital and the APAP with
codeine. [Tr. 31]. Dr. Reitman told DI
Rudy that he was storing the controlled
substances at his office, because he did
not want his wife to find out. [Tr. 32].
14. Dr. Reitman stated that he had no
records (receipts, invoices, log, or
dispensing records) related to the
controlled substances in Moore
Medical’s report. [Tr. 30–31].
15. Investigator Rudy asked him if he
was trading or selling the drugs, and Dr.
Reitman said no. [Tr. 32]. DI Rudy also
stated that she believed his explanation.
[Tr. 47–48]. At this hearing, Dr. Reitman
stated that the drugs were for his
personal use. He never sold them or
dispensed them to anybody. [ALJ Exh.
3 at 2; Tr. 81].
16. Investigator Rudy asked the
Respondent if he realized that he was
violating DEA policy, and he said yes.
[Tr. 32].
17. At that point, Investigator Rudy
left without conducting an inventory,
because she wanted to report this
unique situation to her supervisor. [Tr.
33, 46]. Investigator Rudy had no way
of conducting an inventory, because Dr.
Reitman had no records to compare
with the number of pills on hand. [Tr.
46, 47]. Her supervisor told her to seek
a voluntary surrender of both his
registration and the controlled
substances, which she did. [Tr. 33, 45].
However, Dr. Reitman refused to
voluntarily surrender the controlled
substances or his registration until after
he had spoken with his attorney. [Tr. 33,
45]. Investigator Rudy stated that she
did not think it was unusual for Dr.
Reitman to want to speak to an attorney
and that he had a right to do so. [Tr. 43–
44].
18. However, Investigator Rudy did
tell Dr. Reitman to keep the controlled
substances locked in the cabinet. [Tr.
41].
19. On July 13, 2009, DI Rudy
returned to Dr. Reitman’s office, this
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
time with a different investigator,
Investigator Theresa Grant, to seek a
voluntary surrender of his registration.
[Tr. 34–5]. Dr. Reitman, acting pursuant
to the advice of his attorney, refused to
surrender both the controlled
substances and his DEA Certificate of
Registration to DEA Diversion
Investigators Rudy and Grant. [ALJ Exh.
3 at 2; Tr. 35].
20. On July 15, 2009, Investigator
Rudy again met with Dr. Reitman at his
office. [Tr. 35]. On this occasion, she
was accompanied by Special Agent
Rockwell Herron. [Tr. 35]. Dr. Reitman
voluntarily surrendered the controlled
substances in question to Investigator
Rudy and Special Agent Herron. [ALJ
Exh. 3 at 2; Tr. 35–36]. Investigator
Rudy seized the controlled substances
and gave Dr. Reitman a receipt (DEA–
12) for the drugs. [Tr. 36, 41, 44].
21. Investigator Rudy and Agent
Herron seized the Butalbital and the
APAP with codeine, which were being
stored in the same locked cabinet. [Tr.
36].
22. Investigator Rudy seized four
sealed bottles and one partial bottle of
APAP with codeine. [Tr. 36]. These
drugs were in both 500- and 100-count
bottles. [Tr. 47].
23. Investigator Rudy seized eight
sealed bottles and one partial bottle of
Butalbital with codeine. [Tr. 36–37].
These drugs were in 100-count bottles.
[Tr. 47].
24. Investigator Rudy stated there was
a significant difference between what
was seized and the amount ordered
according to the Moore Medical records.
She is unsure of the amount that was in
fact seized. [Tr. 47, 48–49]. She stated
that he ordered 128 bottles of Butalbital
and 32 bottles of APAP with codeine.
However, there were only eight bottles
of Butalbital and four bottles of APAP
with codeine. [Tr. 48–9]. Investigator
Rudy could not provide a specific
number of the amount of pills he had on
hand. [Tr. 49–50]. Therefore, Dr.
Reitman had at least 800 dosage units of
each controlled substance on hand at
this time.
25. Investigator Rudy took these drugs
to the San Diego Field Division’s
evidence room. They are now at the
Southwest Lab in Vista, San Diego. [Tr.
37].
26. Investigator Rudy stated that Dr.
Reitman told her that he was taking
three to six pills per day. [Tr. 53].
27. Sometime in August, Investigator
Rudy received an updated report from
Moore Medical, which contained
information related to controlled
substances purchased by Dr. Reitman
from Moore Medical from March 19,
2009 through August 27, 2009. [Govt.
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
Exh. 4; Tr. 38, 39]. She received this
report from Tracy Lofquist from Moore
Medical’s Regulatory Affairs
department. [Tr. 38]. Again, this
document shows that Dr. Reitman
ordered Butalbital APAP with codeine
and APAP with codeine. [Tr. 39].
Patrick Early, Vice President of
Regulations and Operational Affairs at
Moore Medical tallied Dr. Reitman’s
orders of controlled substances from
January 1, 2005, through August 27,
2009. [Govt. Exh. 5 at 2–3]. He stated
that Dr. Reitman ordered 11,600 dosage
units of APAP with Codeine and 12,800
dosage units of Butalbital APAP
Caffeine with Codeine in that time
(which is four years, seven months, and
twenty-seven days, or seventeenhundred days). However, since
Investigator Rudy seized at least 800
dosage units of APAP with Codeine and
another 800 dosage units of Butalbital
APAP Caffeine with Codeine, Dr.
Reitman could have only ingested
approximately 10,800 dosage units of
APAP with Codeine and approximately
12,000 dosage units of Butalbital APAP
with Codeine during that time.
[Compare Govt. Exh. 5 at 2–3 with Tr.
36–37, 47]. This is an approximate
average of six APAP with Codeine per
day and an average of seven Butalbital
APAP Caffeine with Codeine per day for
a maximum total of thirteen pills per
day. [Govt. Exh. 5 at 2–3].
28. Dr. Reitman’s last order was
placed on May 22, 2009. He has not
ordered any controlled substances from
Moore Medical since. [Govt. Exh. 4; Tr.
39–40, 44]. The DEA’s ARCOS database,
which stands for Automated Reporting
and Consolidated Ordering System,
tracks controlled substances orders. [Tr.
40]. Investigator Rudy used ARCOS to
confirm that Dr. Reitman has made no
controlled substances orders since May
22, 2009. [Tr. 40].
29. Dr. Reitman still has the ability to
order controlled substances. [Tr. 40, 88].
He has not ordered any, but he has
prescribed controlled substances to his
patients. [Tr. 88].
30. Dr. Reitman stated that, other than
an action related to the events that led
to this hearing, Dr. Reitman has only
had one prior interaction with the
Medical Board of California. [Tr. 81–2].
The Medical Board of California placed
Dr. Reitman on probation from 2002
until 2004, because he lost a malpractice
case and the Board felt he had
improperly treated a patient. The Board
has taken no other action on his medical
license. [Tr. 56–57, 101–02]. The 2002
probation had nothing to do with his
abuse of codeine. [Tr. 102].
E:\FR\FM\30SEN1.SGM
30SEN1
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
C. Dr. Reitman’s Addiction
31. Dr. Reitman stated that he
considers himself to be a recovered drug
addict. He admits to abusing controlled
substances, stating that he began to
abuse Butalbital with codeine and
APAP with codeine in about 2002 or
2003. Initially, he was prescribed these
drugs by his private physician to treat
headaches. Then, when he was at the
point that he was taking more than 100
per month, he began ordering them for
himself from Moore Medical. [Tr. 59–60,
77].
32. Dr. Reitman stated that he began
getting essentially migraine headaches
when he was about five or six years old.
[Tr. 77]. They abated until the late 1990s
when he was suffering from cervical
stenosis and neck pain. [Tr. 78].
33. The Respondent admits that he
knew that he ‘‘was taking an ever larger
dose of medication,’’ but that he needed
the medication because he was having
the headaches. Dr. Reitman stated, ‘‘I
was stupid at the time. I probably
should have asked to go to a rehab
program or something to get myself off
it at that time. I just didn’t. I made a
tremendous mistake.’’ [Tr. 87].
34. Since July of 2009, Dr. Reitman
has had few headaches, and he is able
to treat these headaches with Imitrex or
ibuprofen. [Tr. 78]. Dr. John E. Milner
told Dr. Reitman that these headaches
are codeine withdrawal headaches that
may last from 18 to 24 months. [Tr. 78].
Also, Butalbital is a barbiturate. [Tr.
103]. However, Dr. Milner told Dr.
Reitman that he did not think that Dr.
Reitman was ever addicted to Butalbital,
just the codeine. [Tr. 104]. Today, if he
needs a controlled substance, he has
two physicians, a neurologist and a
primary physician, who can prescribe
that for him. [Tr. 79].
35. Dr. Reitman candidly admitted
that the Moore Medical report does not
paint a clear picture of his selfprescribing practices. [Tr. 60–61]. The
document begins with purchases on
March 8, 2005. However, the
Respondent admits to ordering for
himself from Moore Medical since
approximately 2002. [Tr. 60–61]. He
stated that prior to 2002, he had been
receiving his prescriptions from his
private physician for about two years.
[Tr. 61]. Dr. Reitman also stated that the
Moore Medical report reflects all of the
kinds of controlled substances he
purchased from Moore Medical. [Tr. 81].
He did not purchase controlled
substances from any other distributor.
[Tr. 63].
36. Dr. Reitman said that he increased
the amount of drugs that he was taking
to the point that he was ingesting
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
between eight and twelve
(approximately 660 mg) per day. [Tr.
61–63].
37. Dr. Reitman states that he kept no
records from Moore Medical. [Tr. 63–
64]. He states he has no dispensing log,
because he didn’t dispense to anyone
but himself. [Tr. 64].
D. Dr. Reitman’s Treatment
1. Dr. Stephen Reitman
38. Dr. Reitman stated that he does
not remember telling Investigator Rudy
about his problem, but that he did tell
Dr. William Friedel on the night of July
8, 2009. Dr. Friedel recommended he
speak with an attorney and attend a
meeting of the Physician Well-Being
Committee at Grossmont Hospital,
which occurs once every three months
and happened to be the next day, July
9, 2009. Dr. Reitman attended the WellBeing Committee meeting where he told
Dr. Calaprete of his drug problem. [Tr.
64–65, 68, 69, 102–03]. He continues to
attend these committee meetings. [Tr.
69, 73].
39. Dr. Friedel also told Dr. Reitman
about a diversion program. [Tr. 64–65,
74]. Dr. Reitman has also signed a
Pacific Assistance Group (‘‘PAG’’)
contract with Duane Rogers which
‘‘spells out what I will do and what will
happen to me if I am found to be
positive of substances or alcohol.’’ [Tr.
74, 89]. He has to not abuse controlled
substances, attend diversion meetings
twice a week, and allow random urine
tests for a minimum of four to five times
per month for three years. [Tr. 74, 90].
All of his urine tests have been negative
since he began the program in July of
2009. [Tr. 74, 90]. He hasn’t missed any
meetings, but has been excused from a
few when he was out of town. [Tr. 90–
91]. If he breaks a term of the contract,
he can be told that he cannot go to work
until he has had two negative urine
tests. [Tr. 91]. However, if he violates a
term of this contract, it is not reported
to the California Medical Board or to the
DEA. [Tr. 91].
40. Dr. Reitman also attends
Alcoholics Anonymous (‘‘AA’’)
meetings. [Tr. 75]. He completed a 90 in
90 program, which means going to a
minimum of 90 meetings in 90 days.
Now, he attends AA meetings two to
three times a week and meets with his
sponsor, Philip Shapiro, on the phone
or in person once per week. [Tr. 75]. Dr.
Reitman attends AA meetings instead of
Narcotics Anonymous (‘‘NA’’) meetings,
because he did not feel comfortable at
NA meetings. He said the participants
were all younger, 17 to 30 years old and
used four-letter words. Many had been
to prison. [Tr. 76]. Several people at the
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
60893
AA meetings are also substance abusers
or poly-drug abusers. [Tr. 76].
41. With regards to his addiction to
controlled substances, Dr. Reitman also
told two of his children who live in the
area and his wife the following Monday
when she returned from a trip abroad.
[Tr. 67–68]. However, he did not admit
to anyone that he had a problem until
he was confronted by Investigator Rudy.
[Tr. 65–66].
42. The last time he ingested a
controlled substance was on the
morning of July 8, 2009, when he took
two tablets of the 60 mg Tylenol with
codeine and two tablets of the Butalbital
with codeine. He has since been
substance free for over nine months.
[Resp. Exh. 3 at 1; Tr. 66, 71].
43. On August 3, 2009, Dr. Reitman
voluntarily entered an inpatient
program at Rancho L’Abri in the East
County of San Diego for 30 days. [Resp.
Exh. 1, 2, 3; Tr. 70, 71, 72]. The program
is run by Dr. John Milner. [Tr. 71]. Dr.
Reitman conducted a five-day
detoxification period at home prior to
entering the program at Rancho L’Abri.
[Tr. 72]. Through the program, Dr.
Reitman learned that while he was selfprescribing codeine, he was most likely
experiencing more headaches as a result
of daily codeine withdrawal. [Tr. 73].
He states he has had no desire to take
codeine since he stopped and that he
feels like a different person. [Tr. 73, 79].
Though he still gets some headaches, he
states that they are the result of ongoing
changes in the mind and body resulting
in his cessation of using codeine. [Tr.
88–89].
44. The Respondent stated that he has
had a 100% recovery and that he is
100% committed to sobriety. [Tr. 80,
88]. When asked, he stated, ‘‘Definitely.
I never want to go backwards.’’ [Tr. 80].
However, he also notes that it is a
continuing thing and chemical
dependency is something that he has to
be worried about for the rest of his life,
which is why he states that he will
continue to go to AA meetings. [Tr. 88].
Dr. Reitman also states that though he
abused codeine for eight years and has
only been clean for a little over nine
months, he is well on the road to
recovery, and in more than just the early
stages. [Tr. 89].
45. The Respondent offered into
evidence approximately 18 patient
comments about Dr. Reitman from
August 1, 2009, to December 31, 2009,
and from January 1, 2010, to March 23,
2010. [Resp. Exh. 9; Tr. 92–93]. The
comments are mostly positive other
than a few typical criticisms. [Resp.
Exh. 9 at 2]. Additionally, during the
time that he was addicted to codeine,
E:\FR\FM\30SEN1.SGM
30SEN1
60894
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
Dr. Reitman said that he did not receive
any patient complaints. [Tr. 102].
46. The Respondent offered into
evidence a Letter of Compliance from
Duane Rogers, Psy.D., MFT, dated
March 27, 2010.7 [Resp. Exh. 7; Tr. 95–
6]. Therein, Dr. Rogers states that Dr.
Reitman ‘‘has fully participated and
complied with the physicians
monitoring program from the above date
[ ] as a self-referred voluntary
participant.’’ [Resp. Exh. 7]. The letter
also states: ‘‘To date, all tests are
negative for all drugs of abuse and
alcohol.’’ [Id.].
47. The Respondent also offered into
evidence the office notes from a
neurologic evaluation of Dr. Reitman by
Dr. Boris Khamishon, Dr. Reitman’s
treating neurologist who has been
helping him with his headaches. [Resp.
Exh. 8; Tr. 96–7].
mstockstill on DSK4VPTVN1PROD with NOTICES
2. Dr. Peter Colaprete
48. Dr. Peter Colaprete is a physician
at Grossmont Hospital. [Tr. 108–9]. He
began working with Dr. Reitman in
1987. [Tr. 109]. He has known Dr.
Reitman for 23 years and considers him
to be a friend. [Tr. 113]. Dr. Colaprete
has an undergraduate degree in biology
and chemistry. He then attended
medical school, after which he
completed a residency in emergency
medicine, a fellowship in critical care
medicine, and another residency in
hyperbaric medicine. [Tr. 108].
49. Dr. Colaprete has been the
chairman of the Grossmont Hospital
Wellness Committee for approximately
ten years, and has been a member of the
committee for approximately twenty
years. [Tr. 109]. The committee was
mandated by the State of California in
the 1970s with the purpose of helping
physicians that are addicted to
medications or alcohol or are suffering
from dementia or psychiatric illness.
[Tr. 109–10]. Prior to the establishment
of these types of committees, doctors
such as Dr. Reitman might have simply
lost their license. This is a way to allow
troubled doctors to continue to practice
if the committee and the State feel that
this is an option. There are ten members
on the committee, and all have been
there for more than five years. [Tr. 114].
At least one member of the committee
has to have been a physician with a
former addiction problem. [Tr. 119]. The
committee meets quarterly, conducts
random urine screens, and establishes a
contract with the doctors that must be
followed. The committee also stays in
7 Although
the letter is dated March 27, 2009, the
parties agreed that this was a typographical error
and the actual date was March 27, 2010. [Tr. 95–
96].
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
contact with the doctors as well as their
physicians. [Tr. 114–15, 116]. The
physician usually must attend these
meetings for two or three years. [Tr. 116,
118].
50. In approximately July of 2009, it
came to Dr. Colaprete’s attention that
Dr. Reitman would need the assistance
of the Wellness Committee. [Tr. 110].
Dr. Reitman has attended three meetings
since that time. [Id.]. Dr. Reitman told
the committee of his recurring
headaches, his treatment of those
headaches, and his subsequent selfprescribing of codeine in large amounts.
[Tr. 111].
51. Dr. Colaprete stated that the
committee has not done any urinalysis
tests for Dr. Reitman. [Tr. 115].8 As part
of the contract, twice per month, Dr.
Reitman has to meet with a clinical
psychologist, Duane Rogers, who can
also do screening. [Id.].
52. If the Committee feels that the
physician should not be permitted to
work (i.e. the doctor fails to attend a
meeting, tests positive on a urinalysis,
admits to a relapse, etc.), then they can
recommend this to the hospital’s chief
of staff who can summarily stop that
physician from working. [Tr. 115–16,
117]. This would also be reported to the
Medical Board of California, but not the
DEA. [Tr. 117, 124].
53. Dr. Colaprete is familiar with Dr.
Milner, the director of the Rancho
L’Abri program. [Tr. 111–12]. Dr.
Colaprete stated that Dr. Milner is very
knowledgeable in prescription drugs
and has seen many, many patients. [Tr.
112].
54. With regards to Dr. Reitman’s
recovery, Dr. Colaprete stated that Dr.
Reitman was their ‘‘star physician.’’ Dr.
Colaprete also said, ‘‘He completed the
program as we requested. He’s followed
all our instructions. He’s come to every
meeting we’ve asked him to come to,
and, again, I’ve had, you know scores of
physicians that have been requested to
come to the committee, and I believe Dr.
Reitman is at the top of that list of
people that have completed and have
performed as we requested.’’ [Tr. 112–
13]. Dr. Colaprete stated he intends to
have Dr. Reitman continue to participate
in this program. [Tr. 113].
55. In twenty years on the committee,
Dr. Colaprete has seen approximately
twenty physicians with substance abuse
problems. [Tr. 118]. He has never seen
a physician relapse who seemed very
committed to recovery. [Tr. 119]. He
also stated that having access to drugs
8 However, Duane Rogers has been conducting
urinalysis tests and all have been negative for drugs
‘‘of abuse’’ and alcohol. [Resp. Exh. 7]. Rancho
L’Abri also conducted urinalysis tests, which have
all been negative as well. [Resp. Exh. 4].
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
as well as the ability to write
prescriptions could potentially be a
problem. [Tr. 120]. However, when
asked if he would characterize Dr.
Reitman as being recovered, Dr.
Colaprete stated, ‘‘* * * he’s pretty
close.’’ [Tr. 120]. He also reiterated that
Dr. Reitman is ‘‘on the road to recovery,
if not completely recovered,’’ and he
does not foresee him relapsing. [Tr.
122].
56. Dr. Colaprete stated that Dr.
Reitman ‘‘loves his patients,’’ is ‘‘very
conscientious,’’ and was a ‘‘very
professional physician.’’ [Tr. 122]. At no
point did Dr. Colaprete ever note any
strange behavior on the part of Dr.
Reitman. [Tr. 123–24].
3. Dr. William Friedel
57. Dr. William Friedel is a graduate
of Brown University. He attended Albert
Einstein College of Medicine, interned
at Downstate in Brooklyn, New York,
and returned to Albert Einstein for his
residency in urology. He has been a
practicing urologist in California since
1973. [Tr. 127].
58. Dr. Friedel has known Dr. Reitman
as a friend and colleague for over 35
years. [Tr. 126–27, 138–9]. They belong
to a religious group. They also worked
together at El Cajon Valley Hospital. Dr.
Friedel was Dr. Reitman’s patient until
approximately six or seven years ago
when, after Dr. Friedel had a heart
attack, he began seeing a cardiologist as
his primary physican. [Tr. 127–28].
59. Dr. Friedel stated that, ‘‘as a
sophisticated consumer of medical care
* * * I certainly would not have seen
[Dr. Reitman] if I did not think he was
more than competent.’’ [Tr. 129]. He
also said that his opinion of Dr.
Reitman’s medical abilities was
‘‘excellent.’’ [Tr. 129]. He has observed
Dr. Reitman with patients. Dr. Friedel
testified that Dr. Reitman is an
‘‘excellent physician’’ who ‘‘cares about
his patients and takes good care of
them.’’ [Tr. 134, 141]. During the 2002
to 2009 time frame, he did not suspect
that Dr. Reitman was interacting with
patients while he was under the
influence of a controlled substance. [Tr.
141].
60. In July of 2009, Dr. Reitman told
Dr. Friedel of his years of selfprescribing of controlled substances.
[Tr. 129, 139]. Dr. Friedel advised Dr.
Reitman to meet with Grossmont
Hospital’s Wellness Committee. [Tr.
130]. Dr. Friedel has been a member of
this committee for over 20 years. [Tr.
130–31, 135]. Though he admits he is
not an addictologist, he states that from
a practical point of view, he is very
experienced in addiction issues. [Tr.
131, 135].
E:\FR\FM\30SEN1.SGM
30SEN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
61. Dr. Reitman has since met with
the committee and will continue to meet
with the committee regularly. [Tr. 132,
136]. However, Dr. Friedel stated that
the committee does not really ‘‘monitor’’
physicians, but rather has the doctors
come in and talk with the committee
periodically. The committee also assigns
a mentor to keep in close contact with
the physicians. He is unsure if the
committee has appointed a mentor for
the Respondent. [Tr. 135–36].
62. Dr. Friedel stated that Dr. Reitman
has ‘‘an excellent chance of not abusing
codeine in the future. It’s crystal-ballgazing, as you know. There’s a certain
relapse rate for people who use drugs.
I think * * * it’s unlikely that he would
do that.’’ [Tr. 133]. He added that Dr.
Reitman ‘‘absolutely’’ appears
committed to recovery. [Id.]. He knows
that Dr. Reitman abused controlled
substances for several years and that he
has only been free of controlled
substances for nine months. [Tr. 136].
He could not say that Dr. Reitman is
recovered, but used the more general
term of ‘‘recovering.’’ He compared it to
being cured, stating that ‘‘[y]ou only
know somebody’s cured when they die
and they don’t have it anymore.’’ He
later added, ‘‘It’s like the alcoholic
describing themselves as [a] nondrinking alcoholic.’’ [Tr. 136–37, 140].
63. Dr. Friedel stated that the
committee only sees about one, new
physician with substance abuse
problems every three years. [Tr. 137]. He
has seen physicians relapse even when
they seemed committed to recovery. [Tr.
137].
64. When asked, with regards to a
physician who is addicted to controlled
substances, whether access to controlled
substances would be conducive to
recovery, Dr. Friedel said: ‘‘There’s no
doubt that anybody who has free access
to drugs is more likely to abuse drugs,
and probably the best example I can use
is an anesthesiologist who, as a
profession, are more likely to become
addicted, because the drugs are poorly
accounted for and readily available.
With that analogy, of course, anybody
who has more access to drugs is
probably more likely to abuse that
access. On the other hand, I think Dr.
Reitman’s very committed not to do
this.’’ [Tr. 138].
65. Dr. Friedel stated that Dr. Milner
was ‘‘the guy in addiction medicine
* * * he’s the guy to go to.’’ [Tr. 134].
4. Rabbi Avram Bogopulsky
66. Rabbi Avram Bogopulsky did his
initial training in Muncie, New York
under the tutelage of Rabbi Wein for
eight years, encompassing detailed
study, Talmudic study, rabbinical study,
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
and pastoral care. He then served as an
assistant rabbi in Charleston, South
Carolina for three years. Now he has led
the Beth Jacob Congregation in San
Diego for the past 14 years. [Tr. 144].
67. Dr. Reitman has attended Beth
Jacob for 14 years. [Tr. 144]. Rabbi
Bogopulsky considers him ‘‘one of our
better congregants as far as he attends
daily minion, which is a gathering of a
quorum of ten * * * every single
morning.’’ [Tr. 144]. They talk on a
regular basis. [Tr. 145, 148–9]. Dr.
Reitman is one of two vice presidents of
the congregation. [Tr. 145].
68. Rabbi Bogopulsky, his wife, and
his son are all patients of Dr. Reitman.
[Tr. 145]. Rabbi Bogopulsky stated that
Dr. Reitman is a ‘‘very good doctor.’’ [Tr.
146].
69. In July of 2009, Dr. Reitman came
to Rabbi Bogopulsky for spiritual
guidance related to his years of
addiction and self-prescribing of
controlled substances. [Tr. 146–7].
Rabbi Bogopulsky stated that this came
as a shock, because the Respondent
never appeared to be under the
influence. [Tr. 148]. He stated that Dr.
Reitman ‘‘has an impeccable character
with a deep concern for people * * *
and is a role model in the community.’’
[Tr. 149].
70. Rabbi Bogopulsky testified that Dr.
Reitman showed remorse and was
‘‘absolutely regretful.’’ [Tr. 150]. He also
stated that Dr. Reitman has
‘‘demonstrated to this day, every single
day, a commitment’’ to recovery. [Id.].
He explained that, in Orthodox Judaism,
the Sabbath is a day of holiness. On the
Sabbath, ‘‘we do not use electricity, we
don’t answer the phone, drive,
computers.’’ However, part of the
recovery process requires Dr. Reitman to
call in on a daily basis. Therefore, he
and Rabbi Bogopulsky have an
agreement where Rabbi Bogopulsky
allows Dr. Reitman to essentially bypass
Jewish law and use Rabbi Bogopulsky’s
office phone to call in on the Sabbath.
[Tr. 150–51]. Rabbi Bogopulsky stated
that this allows him to maintain his
religious faith and still carry out his
commitment to recovery. [Tr. 151].
71. Rabbi Bogopulsky also said that he
never suspected Dr. Reitman of abusing
drugs and that he had no inclination
that he was under the influence of any
drugs. [Tr. 152]. He admitted that he is
neither a medical doctor nor an
addiction specialist. However, he
testified that in his position as a
spiritual leader, he has counseled
people with addiction problems before,
but he typically finds a more qualified
counselor to help addicts. [Tr. 152–3].
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
60895
5. Dr. John E. Milner
72. Dr. John E. Milner graduated from
the University of Texas Medical School
in Dallas in 1957. He interned at the
Naval Hospital in Camp Pendleton and
served as a general duty medical officer
until 1961. He was in private practice in
La Jolla, California from 1961–66. He
began psychiatric training in 1966,
eventually completing a child and
adolescent fellowship in psychiatry in
1970. In the mid-1970s, he opened an
alcohol and drug treatment unit in San
Diego, California called Sharp Cabrillo
Hospital. He received a certificate in
addiction medicine in 1986. He also
opened a non-hospital-based treatment
program for alcohol or drug dual
diagnosis patients called Rancho L’Abri.
He has been the medical director at
Rancho L’Abri for more than 25 years.
He indicated that he has probably
treated thousands of patients and
hundreds of physicians with drug and
alcohol issues. [Resp. Exh. 10; Tr. 181–
4, 190].
73. Dr. Reitman came to Rancho
L’Abri as an inpatient on August 3,
2009. [Resp. Exh. 1; Tr. 184–5]. Dr.
Milner’s team, under his direction,
created a treatment plan for Dr.
Reitman. [Resp. Exh. 2; Tr. 186–7]. In
addition, the team also maintains
patient progress notes, which are
reviewed by Dr. Milner. [Resp. Exh. 3;
Tr. 187–8]. The team also conducts
urine toxicology screening and keeps
records of the results. [Resp. Exh. 4; Tr.
189]. When Dr. Reitman arrived at
Rancho L’Abri, his urinalysis results
showed him as negative for both opioids
and barbituates. [Resp. Exh. 4; Tr. 203].
Dr. Reitman continues to receive urine
screens. [Tr. 204].
74. Dr. Milner diagnosed Dr. Reitman
with opioid addiction. He did not
diagnose Dr. Reitman with barbiturate
addiction. He did not know that Dr.
Reitman ordered four times as much
Butalbital as he did APAP with codeine.
[Tr. 200]. Dr. Milner said that Butalbital
is a very mild sedative that can cause a
person to become ‘‘sort of intoxicated’’
in huge doses. [Tr. 201]. He testified that
he never saw any barbiturate
withdrawal symptoms, and ‘‘a person
who’s severely addicted is going to
manifest them.’’ [Tr. 201].
75. By July 2009, Dr. Reitman was
taking approximately 660 mg of codeine
per day. [Tr. 190–91, 202]. Dr. Milner
stated that codeine is very kind on the
human brain, ‘‘so it’s very, very likely,
conceivable, and totally possible that he
can function * * * as normally as he
did with this dose of codeine in him.’’
[Resp. Exh. 6; Tr. 192]. He said that his
team looked extensively for any
E:\FR\FM\30SEN1.SGM
30SEN1
60896
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
evidence that Dr. Reitman failed to
function as a physician during the
period that he was abusing codeine, but
could find no such evidence. [Tr. 192].
76. Dr. Milner testified that Dr.
Reitman arrived at Rancho L’Abri
having already stopped taking codeine.
‘‘He was deeply ashamed, humiliated,
aghast that he had been doing this for
so long.’’ [Resp. Exh. 3 at 1–4; Tr. 192–
93].
77. Dr. Milner said that Dr. Reitman
has been committed ‘‘since the very
beginning’’ to stop using the drugs. [Tr.
193]. To the best of his extensive
knowledge, he stated that Dr. Reitman
has ‘‘rigorously attended all the
recommended behaviors and attitudes
and processes.’’ [Tr. 193–4]. When
asked to rate Dr. Reitman’s commitment
to recovery on a scale of one to ten, Dr.
Milner said, ‘‘Nine. Ten. Yeah, he’s
committed.’’ [Tr. 194]. He also stated
that ‘‘as long as he continues the process
he’s involved in, the risks [of relapse]
are minimal.’’ [Tr. 194]. Dr. Milner
believed that it would be in the interest
of the public to continue to allow Dr.
Reitman to prescribe controlled
substances, and he would expect the
urine monitoring and continued
involvement in his own recovery plan to
continue. [Tr. 195–96]. Admitting that it
is possible for a person who has
demonstrated their commitment to
recovery to relapse, Dr. Milner asserted
that as long as the individual continues
to be monitored and continues to follow
recommended processes, the chances of
relapse are very slim. [Tr. 196–97]. Dr.
Milner knew that Dr. Reitman had
abused for several years and had only
been clean for approximately nine
months. [Tr. 198]. He also stated that the
chance of relapse in the earlier period
of recovery is increased. [Tr. 199].
78. Dr. Milner testified that if a
physician is in the proper monitoring
program, then access to ‘‘one’s drug of
choice’’ would not be harmful. [Tr. 199].
79. Dr. Reitman’s wife was
continuously supportive throughout Dr.
Reitman’s stay at Rancho L’Abri,
providing Dr. Reitman with kosher
meals and attending family sessions.
[Resp. Exh. 3 at 1–4, 6–7].
6. Dr. Sandra Jassmann
80. Dr. Sandra Jassmann received a
medical degree from Medical College of
Virginia in 1969. She had three years of
internal medicine at Cleveland Clinic in
Cleveland, Ohio from 1969 to 1972. She
served two years with the United States
Navy in Charleston, South Carolina
from 1972 to 1974. Then, from July 1,
1974, to June 10, 1976, she participated
in a fellowship in endocrinology at
Sepulveda VA in Sepulveda, California,
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
an affiliate of UCLA. She began working
in San Diego in 1976. [Tr. 207].
81. Dr. Jassmann met Dr. Reitman in
1976 and worked closely with him for
30 years. [Tr. 208]. She considers Dr.
Reitman to be a ‘‘very competent, very
capable, very professional’’ doctor who
has ‘‘the interests of his patients at
heart.’’ [Tr. 208–9, 212].
82. In August of 2009, Dr. Reitman
told Dr. Jassmann that he had an
addiction problem and would be going
into rehab. [Tr. 209]. Dr. Jassmann
stated that she was ‘‘astounded, [] had
no way of knowing, [and] had not
observed anything.’’ [Tr. 210]. He was
‘‘never’’ lethargic, loopy, or seemed to
be under the influence of any
medication during the period from 2002
through 2009. [Id.]. She had never heard
any complaints about Dr. Reitman. [Tr.
211, 212]. Dr. Jassman was aware of the
2002 action by the California Medical
Board. However, she stated that this
does not change her opinion of Dr.
Reitman’s abilities. [Tr. 212–3]. She no
longer works with Dr. Reitman;
however, Dr. Jassmann testified that, if
she did, she would allow him to crosscover her patients. [Tr. 213–4].
83. Dr. Jassmann stated that she felt
confident that Dr. Reitman is able to
conduct his practice successfully with
regards to patients and prescribing. [Tr.
211]. She said that he was an excellent
practitioner of internal and geriatric
medicine. [Tr. 212].
84. Dr. Jassman testified that Dr.
Reitman was remorseful about the fact
that he had abused codeine. [Tr. 211].
7. Philip Shapiro, Esq.
85. Philip Shapiro is an attorney in
San Diego. He went to college at
Southern Illinois for his undergraduate
degree. Then, he attended San Diego
State for his Master’s. For his J.D., he
attended Thomas Jefferson School of
Law. Prior to becoming an attorney, he
served as a special agent with the
United States Secret Service. [Tr. 216–
17].
86. Mr. Shapiro had been addicted to
cocaine. He is currently involved in
Alcoholics Anonymous. He has been
recovering for a total of 11 years. He has
sponsored five people and is currently
Dr. Reitman’s sponsor. [Tr. 217]. Dr.
Reitman is currently undergoing the
twelve-step program, and is on step
four. He is unsure, but he believes that
Dr. Reitman has also completed the 90
in 90 program. Dr. Reitman and Mr.
Shapiro had been talking every day, but
now they talk three to four times per
week on the phone, and 90% of the
time, they meet in person on Sundays.
[Tr. 218–19, 221].
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
87. With regards to Dr. Reitman’s
commitment to recovery, Mr. Shapiro
said, ‘‘I honestly would say that I think
[Dr. Reitman] has the greatest chance of
any person I’ve ever sponsored.’’ [Tr.
219]. However, he also stated that he
has seen other AA members relapse,
even those that were remorseful about
their past addiction and abuse. But, if
the addicted person comes to meetings
and doesn’t abuse between meetings,
then ‘‘he or she will make it.’’ [Tr. 222].
Also, having easy access to one’s drug
of choice can make it much tougher to
stay sober. [Tr. 223]. Mr. Shapiro has
seen individuals with 22 years of
sobriety relapse. He stated that it is the
individual’s level of commitment to
sobriety that seems to determine
whether or not they are going to relapse.
[Tr. 223–24].
88. Mr. Shapiro said that Dr. Reitman
has been very open about his problem
from the beginning. [Tr. 219]. He does
not blame anyone but himself. [Tr. 220].
89. Mr. Shapiro testified that he
would feel comfortable going to Dr.
Reitman as his personal physician. In
fact, he sent his daughter to Dr.
Reitman. [Tr. 220].
8. Christine Kuwazaki
90. Christine Kuwazaki has known Dr.
Reitman for 26 years. She is his back
office assistant and his practice
manager, doing billings, claims and
charges. She works closely with Dr.
Reitman on a daily basis. [Tr. 226–27,
233].
91. Ms. Kuwazaki stated that Dr.
Reitman is ‘‘very caring, very ethical,
and conscientious with patient care.’’
[Tr. 228, 231, 235].
92. However, she did not know that
he was using his DEA Registration to
order controlled substances for personal
use. [Tr. 235].
93. To her knowledge, Dr. Reitman
does no dispensing at his practice. No
pharmacy representatives leave samples
at the practice. [Tr. 236].
94. From the period of 2002 through
the present, Dr. Reitman has only had a
couple of patient complaints. [Resp.
Exh. 9 at 2; Tr. 228]. She described them
as ‘‘typical.’’ [Tr. 234].
95. Dr. Reitman told Ms. Kuwazaki
that he had been abusing codeine on
July 8, 2009. Up until that point, she did
not see any evidence of him being under
the influence of drugs. [Tr. 229–30]. He
told her that he was going into rehab.
She helped him reschedule patients
during this time. [Tr. 230].
96. Prior to that time, she did not
know that, at his office, he stored the
drugs he self-prescribed. [Tr. 234].
97. Ms. Kuwazaki knew that Dr.
Reitman had a problem with headaches.
E:\FR\FM\30SEN1.SGM
30SEN1
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
She could tell when he had a ‘‘really
bad’’ headache, because he looked ill
and would have to go home for the day.
[Tr. 230–31]. Now that Dr. Reitman has
completed rehabilitation, Ms. Kuwazaki
stated that he looks relieved and
focused. [Tr. 231].
98. Ms. Kuwazaki does not think that
his ability to write controlled substance
prescriptions would be a problem for
Dr. Reitman. [Tr. 232]. Ms. Kuwazaki
stated that she would trust him to be her
own personal doctor. [Tr. 232–3].
E. Medical Board of California
99. On March 17, 2010, the Medical
Board of California (‘‘Board’’) filed an
accusation against Dr. Reitman for ‘‘self
administering a dangerous drug,’’
‘‘violation of drug statutes and
regulations,’’ and ‘‘general
unprofessional conduct.’’ [Govt. Exh. 6].
However, the Record contains no
evidence that the Board has conducted
a hearing or imposed any restrictions on
the Respondent’s medical license.
IV. Conclusions of Law and Discussion
mstockstill on DSK4VPTVN1PROD with NOTICES
A. Position of the Parties
1. The Government
The Government asserts that the
Respondent’s continued registration is
inconsistent with the public interest.
[Government’s Proposed Findings of
Fact and Conclusions of Law (‘‘Govt.
Brief’’) at 10].
First, the Government states that the
Medical Board of California has filed an
accusation against the Respondent.
[Govt. Brief at 5]. While admitting that
no final action has been taken on the
accusation, the Government avers that
the sanction being sought is revocation
or suspension of his medical license.
The Government concludes that this
action, nonetheless, ‘‘reflects the
Board’s recommendation as to
Respondent’s continued ability to
practice medicine in the State of
California.’’ [Govt. Brief at 5–6].
Next, the Government contends that
the Respondent’s behavior was ‘‘not an
isolated incident of misuse, but was a
continued pattern of behavior that
continued over a seven year period.’’
[Govt. Brief at 6]. Further, the
Government notes that Respondent
‘‘was not compliant with Federal law or
the laws of the State of California.’’ [Id.].
The Government asserts that the
Respondent was indeed a dispenser,
because he dispensed to himself, and is
thus subject to Federal recordkeeping
requirements, with which he did not
comply. [Govt. Brief at 6–7].
Respondent’s actions in self-prescribing
and administering controlled substances
also violated California law. [Govt. Brief
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
at 7–8]. The Government contends that
these violations ‘‘weigh in favor of
finding that Respondent’s continued
registration would be inconsistent with
the public interest.’’
Third, the Government notes that the
Respondent was initially prescribed the
controlled substances he later ordered
for his own abuse. According to the
Government, this does not negate the
fact of his misdeeds. [Govt. Brief at 8].
The Respondent exploited his
controlled substances registration and
did not ask his physician to continue
prescribing, because he knew that his
intake of controlled substances was a
problem. [Govt. Brief at 8–9].
The Government goes on to argue that
though it appears Respondent’s
addiction never adversely affected his
practice, Respondent was merely able to
hide his addiction from everyone
around him for seven years. [Govt. Brief
at 9]. According to the Government, this
exemplifies his ability to conceal future
abuse. [Id.].
The Government next notes that,
though the Respondent voluntarily
entered a variety of rehabilitative efforts,
‘‘which no doubt demonstrates a
commitment to staying clean and sober
* * * he has only been sober for a
period of approximately eleven months.
He abused controlled substances for a
period of seven years.’’ [Id.].
Additionally, the Government notes the
chances that the Respondent will
relapse could be enhanced, because he
is in the ‘‘early stages of recovery,’’ and
because, if he is permitted to retain his
registration, he would have access to
controlled substances. [Govt. Brief at
9–10].
In conclusion, the Government states
that it ‘‘has met its burden in proving
that the Respondent’s continued
registration is inconsistent with the
public interest.’’ [Govt. Brief at 10].
Therefore, Dr. Reitman’s registration
should either be revoked or,
alternatively, suspended for one year
and subject to conditions for three years
upon reinstatement. [Govt. Brief at
10–11].
2. The Respondent
The Respondent argues that his
continued registration is not
‘‘inconsistent with the public interest’’
pursuant to 21 U.S.C. 824(a).
[Respondent’s Post-Hearing Proposed
Findings of Fact, Conclusions of Law,
and Argument (‘‘Resp. Brief’’) at 1].
The Respondent notes that Dr.
Reitman has been subjected to no
adverse recommendation by the state
licensing board and also has no
convictions under Federal or State laws.
[Resp. Brief at 12, 13]. The Respondent
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
60897
further adds that Dr. Reitman is
experienced in handling controlled
substances and, ‘‘exclusive of the
subject at issue in this case, Dr. Reitman
has been responsible in his distribution
of controlled substances and compliant
with DEA laws.’’ [Resp. Brief at 13].
The Respondent next avers that,
despite his own self-prescribing, his
practice during this time period does
not indicate that he placed the public at
risk. [Resp. Brief at 13–15]. He cites one
DEA hearing where a physician was
ultimately found guilty of felonious selfprescribing by subterfuge in a manner
the Respondent considers more
egregious than his own conduct. Mary
Thomson, M.D., Continuation of
Registration With Restrictions, 65 FR
75,969, 75,970 (DEA 2000); [Resp. Brief
at 14]. He also notes that one similarity
between the two cases is that both
doctors harmed no one but themselves.
[Resp. Brief at 15]. Therefore, the
Respondent argues that since his
conduct was not as shocking as the
actions taken by Dr. Thomson, Dr.
Reitman should also be permitted to
continue his registration with
restrictions. [Resp. Brief at 14–15].
The Respondent also states that
‘‘patient care was not affected during
the time frame that Dr. Reitman was
abusing codeine.’’ [Resp. Brief at 15–16].
The Respondent then points out that
he has fully accepted responsibility for
his actions and has minimal risk of
relapsing. [Resp. Brief at 16–17]. He
cites two DEA cases for the proposition
that ‘‘the paramount issue is not how
much time has elapsed since (the
Respondent’s) unlawful conduct, but
rather, whether during that time (the)
Respondent has learned from his past
mistakes and has demonstrated that he
would handle controlled substances
properly if entrusted with [a] DEA
registration.’’ John Porter Richard, D.O.,
61 FR 13,878 (DEA 1996); Leonardo v.
Lopez, M.D., 54 FR 36,915 (DEA 1989);
[Resp. Brief at 18]. Therefore, the
Respondent is arguing that he has made
the appropriate showing and it is thus
reasonable for Dr. Reitman to maintain
his DEA Registration at this time. [Resp.
Brief at 18].
Lastly, the Respondent concludes by
stating that the ‘‘public interest will not
be served by revoking Dr. Reitman’s
DEA registration.’’ [Resp. Brief at 18].
‘‘Although his lifelong battle with
headaches resulted in his eventual
addiction to codeine, since being
approached by the DEA, he has taken
every conceivable step toward
rehabilitation, and his rehabilitative
efforts have paid off.’’ [Id.].
Thus, the Respondent concludes by
stating that he ‘‘respectfully requests
E:\FR\FM\30SEN1.SGM
30SEN1
60898
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
that he be permitted to maintain his
DEA Registration, and is open to any
conditions that will ensure his
continued compliance with DEA
registration requirements.’’ [Resp. Brief
at 19].
B. Statement of Law
Pursuant to 21 U.S.C. 824(a)(4), the
Deputy Administrator 9 may revoke a
DEA Certificate of Registration if she
determines that the continuance of such
registration would be ‘‘inconsistent with
the public interest’’ as determined
pursuant to 21 U.S.C. 823(f). Section
823(f) requires that the following factors
be considered:
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The applicant’s experience in
dispensing, or conducting research with
respect to controlled substances.
(3) The applicant’s conviction record under
Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety.
mstockstill on DSK4VPTVN1PROD with NOTICES
21 U.S.C. 823(f).
The factors may be considered in the
disjunctive: The Deputy Administrator
may properly rely on any one or a
combination of these factors, and may
give each factor the weight she deems
appropriate, in determining whether a
registration should be revoked or an
application for registration denied.
David H. Gillis, M.D., 58 FR 37,507,
37,508 (DEA 1993); see also D&S Sales,
71 FR 37,607, 37,610 (DEA 2006); Joy’s
Ideas, 70 FR 33,195, 33,197 (DEA 2005);
Henry J. Schwarz, Jr., M.D., 54 FR
16,422, 16,424 (DEA 1989).
Also, in an action to revoke a
registrant’s certificate, the DEA has the
burden of proving that the requirements
for revocation are satisfied. 21 CFR
1301.44(e). The burden of proof shifts to
the Respondent once the Government
has made its prima facie case. Shatz v.
U.S. Dept. of Justice, 873 F.2d 1,089,
1,091 (8th Cir. 1989); Medicine Shoppe,
73 FR 364 (DEA 2008); see also Thomas
Johnston, 45 FR 72,311 (DEA 1980).
1. Factor One: Recommendation of the
Appropriate State Licensing Board
The Medical Board of California has
not recommended that Dr. Reitman’s
license be revoked. [FOF 2]. The fact
that the Medical Board of California has
currently authorized the Respondent to
9 The Deputy Administrator has the authority to
make such determinations pursuant to 28 CFR
0.100(b) and 0.104 (2009).
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
practice medicine is not dispositive in
this administrative determination as to
whether continuation of a registration is
consistent with the public interest.
Patrick W. Stodola, M.D., 74 FR 20,727,
20,730 (DEA 2009); Jayam Krishna-Iyer,
74 FR 459, 461 (DEA 2009). The
ultimate responsibility to determine
whether a registration is consistent with
the public interest has been delegated
exclusively to the DEA, not to entities
within state government. Edmund
Chein, 72 FR 6,580, 6,590 (DEA 2007),
aff’d, Chein v. DEA, 533 F.3d 828 (D.C.
Cir. 2008), cert. denied, __ U.S. __, 129
S.Ct. 1033 (2009). Although not
dispositive, state board decisions are
relevant on the issue of granting or
denying a DEA application. See Gregory
D. Owens, D.D.S., 74 FR 36,751, 36,755
(DEA 2009); see Martha Hernandez,
M.D., 62 FR 61,145, 61,147 (DEA 1997).
Dr. Reitman is currently licensed to
practice medicine in California, License
Number G25924. [FOF 2]. The
California Medical Board has not taken
any formal action to limit Respondent’s
right to practice medicine nor has it
recommended limiting his ability to
prescribe controlled substances. [FOF
2]. However, it has filed an accusation
against the Respondent. Although, as
previously stated, the Board has taken
no final action. [FOF 99]. I disagree with
the Government’s argument that this
accusation ‘‘reflects the Board’s
recommendation as to the Respondent’s
continued ability to practice medicine
in the State of California.’’ [Govt. Brief
at 6]. Rather, it is the Board’s ultimate
decision that serves as a
recommendation, not merely the
investigation.
Thus, I find that this factor falls
neither for nor against revocation.
2. Factor Three: Conviction Record
The Record contains no evidence that
the Respondent has any convictions
relating to the manufacture,
distribution, or dispensing of controlled
substances. Therefore, this factor also
does not fall in favor of revocation.
3. Factors Two and Four: Applicant’s
Experience in Dispensing Controlled
Substances and Compliance With
Applicable State, Federal or Local Law
The record revealed that the
Respondent committed recordkeeping
violations. [FOF 14, 17, 24, 37]. ‘‘Every
registrant manufacturing, distributing,
or dispensing a controlled substance or
substances shall maintain, on a current
basis, a complete and accurate record of
each such substance manufactured,
received, sold, delivered, or otherwise
disposed of by him.’’ 21 U.S.C.
827(a)(3), 842(a)(5). Moreover, ‘‘[r]ecord-
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
keeping is one of the CSA’s central
features,’’ and ‘‘a registrant’s accurate
and diligent adherence to this obligation
is absolutely essential to protect against
the diversion of controlled substances.’’
Paul H. Volkman, M.D., 73 FR 30,630,
30,644 (DEA 2008), aff’d 567 F.3d 215,
224 (6th Cir. 2009).
The Respondent did not dispense
medication to anyone but himself. [FOF
15]. Regardless, a physician is required
to keep accurate records readily
available with regards to all controlled
substances received and distributed. 21
U.S.C. 827(a)(3), 842(a)(5). According to
21 U.S.C. 827(c), a physician is often
exempt from the recordkeeping
requirements of 21 U.S.C. 827(a)(3)
when the physician is only prescribing
‘‘in the lawful course of their
professional practice.’’ However, Dr.
Reitman’s unique situation involves a
doctor who ordered 24,400 tablets of
controlled substances over
approximately four and one-half years,
a large portion of which were dispensed
for his personal use, and not ‘‘in the
lawful course’’ of his professional
practice, although the rest of the time he
was indeed only prescribing. [FOF 4,
27]. Thus, I agree with the DEA that the
Respondent was operating as a
‘‘dispenser’’ as that term is defined in 21
CFR 1300.01(b)(11).10 Yet, Dr. Reitman
admitted that he kept none of those
required records [FOF 14, 37], which is
a violation of 21 CFR 1304.21–22.11
Therefore, the Respondent violated DEA
regulations.
The Respondent’s administration of a
controlled substance to himself is also a
violation of both Federal and California
law. Under California Business and
Professions Code, Section 2239(a), ‘‘the
use or prescribing for or administering
to himself or herself, of any controlled
substance [ ] constitutes unprofessional
conduct.’’ Cal. Bus. & Prof. Code 2239
(West 2010). Also, ‘‘[n]o person shall
prescribe, administer, or furnish a
controlled substance for himself.’’ Cal.
Health & Safety Code 11170 (West
2010). Additionally, ‘‘[n]o person shall
obtain or attempt to obtain controlled
substances * * * (1) by fraud, deceit,
10 ‘‘The term dispenser means an individual
practitioner, institutional practitioner, pharmacy or
pharmacist who dispenses a controlled substance.’’
21 CFR 1300.01(b)(11).
11 ‘‘(a) Every registrant required to keep records
pursuant to 1304.03 shall maintain on a current
basis a complete and accurate record of each such
substance manufactured, imported, received, sold,
delivered, exported, or otherwise disposed of by
him/her * * *’’ 21 CFR 1304.21. ‘‘Each person
registered or authorized [ ] to manufacture,
distribute, dispense, import, export or conduct
research with controlled substances shall maintain
records with the information listed below.’’ 21 CFR
1304.22.
E:\FR\FM\30SEN1.SGM
30SEN1
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
misrepresentation, or subterfuge; or [2]
by the concealment of a material fact.’’
Cal. Health & Safety Code 11173. Here,
the Respondent admitted to ordering
controlled substances for himself and
obtained these controlled substances
from Moore Medical while concealing
the fact that he was dispensing to
himself. [FOF 12, 15]. This is a violation
of California law and, by extension,
Federal law. Although the Respondent
did not use prescriptions, he dispensed
controlled substances without a
prescription, which violated Federal
statutory and regulatory provisions. See
21 U.S.C. 829; 21 CFR 1306.04.
Therefore, because the Respondent
thus violated DEA record-keeping
requirements, and because the
Respondent self-administered, I find
that this factor falls in favor of
revocation, and the Government has
thus met its prima facie burden.
mstockstill on DSK4VPTVN1PROD with NOTICES
4. Factor Five: Such Other Conduct
Which May Threaten the Public Health
and Safety
While acknowledging that the
Government has met its prima facie
burden, I find that the inquiry does not
end here. Rather, when assessing the
appropriate remedy in a particular case,
the Deputy Administrator should
consider all facts and circumstances at
hand. See Hernandez, 62 FR at 61,147.
Though Dr. Reitman was selfprescribing, the evidence suggests that,
initially, he was doing so to treat a
medical condition. [FOF 31]. Though
the Government argues that this should
not be considered as a mitigating factor
[Govt. Brief at 8–9], in the past, the
Deputy Administrator has considered
this to be a mitigating factor. Dennis
Robert Howard, M.D., Grant of
Restricted Registration, 62 FR 32,658,
32,662 (DEA 1997) (The then acting
Deputy Administrator noted, ‘‘There is
no evidence in the record that any of the
drugs were taken for other than a
legitimate medical purpose. Also, there
is no evidence that Respondent has
since taken any medication that was not
prescribed for him by another
physician.’’). Similarly, Dr. Reitman had
intense headaches that led to
dependence. [FOF 31–33]. The Record
contains no evidence that Dr. Reitman
was using these controlled substances in
order to produce a ‘‘high.’’ Now, he has
two doctors that can prescribe
controlled substances for him if
necessary. [FOF 34, 47]. Therefore, I
find that Dr. Reitman’s desire was to
treat a genuine medical problem, and
that this should at least serve as a
mitigating factor. See Howard, 62 FR at
32,661.
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
There is evidence that, though Dr.
Reitman self-prescribed, this did not
impair his ability to provide competent
care to his patients. [FOF 59, 68–69, 75].
He hurt no one other than himself.
Though the Government argues that this
simply demonstrates his skills in
subversion [Govt. Brief at 9], in
Thomson, the Deputy Administrator
stated: ‘‘Fortunately for Respondent’s
patients, and for Respondent herself,
there is no evidence that Respondent’s
illicit drug abuse harmed any others
than herself, and further, there is no
evidence that Respondent’s patients
failed to receive needed medications.’’
Mary Thomson, M.D., Continuation of
Registration, 65 FR 75,969, 75,972 (DEA
2000). Likewise, Dr. Milner stated that
it is ‘‘very likely’’ that Dr. Reitman was
able to function normally while taking
660mg of codeine per day. [FOF 75]. Dr.
Milner also stated that he searched for
indications that Dr. Reitman failed to
function as a physician during the
period that he was addicted to codeine;
he could find no such evidence. [Id.].
Other health care professionals stated
that at no point did Dr. Reitman appear
to be under the influence. [FOF 56, 59,
82, 95]. Therefore, I find it to be at least
a mitigating factor that Dr. Reitman’s
self-prescribing did not impair his
ability to conduct his duties as a
physician.
Despite Dr. Reitman’s efforts at
rehabilitation, the Government asserts
that the Respondent has only been
‘‘clean’’ for approximately eleven
months, and that this is not enough time
to be sure that he will not relapse. [Govt.
Brief at 9–10]. As the Deputy
Administrator has previously
determined, ‘‘[t]he paramount issue is
not how much time has elapsed since
[the Respondent’s] unlawful conduct,
but rather, whether during that time
[the] Respondent has learned from past
mistakes and has demonstrated that he
would handle controlled substances
properly if entrusted with a DEA
registration.’’ Leonardo v. Lopez, M.D.,
54 FR 36,915 (1989). It is clear by the
Respondent’s actions since being
confronted by the DEA that he is
dedicated to rehabilitation. [FOF 12, 31,
33, 38, 40, 42–44, 46, 50, 54–55, 62, 64,
73, 77, 86–88]. Specifically, he
immediately entered not just one but
various treatment programs. [FOF 38,
39, 40, 43, 50, 73]. Numerous urinalysis
tests have been conducted; they have all
been negative. [FOF 46, 73].
The Government further maintains
that Dr. Reitman is more likely to
relapse if he has access to his drug of
abuse. [Govt. Brief at 10]. Though three
witnesses did state that the possibility
of relapse was greater in such cases, Dr.
PO 00000
Frm 00101
Fmt 4703
Sfmt 4703
60899
Friedel added that any doctor with
access to a controlled substance is more
likely to abuse the controlled substance.
[FOF 64]. The witnesses also
emphatically stated their opinion that
Dr. Reitman was well on the road to
recovery. [FOF 54, 55, 62, 64, 77].
Therefore, I find that, under the
particular circumstances of this case,
nine months is not such a short recovery
period that it should serve as grounds
for revocation.
Additionally, the Respondent has
demonstrated remorse and a dedication
to overcoming his addiction and
preventing future mis-judgments. Under
Agency precedent, where the
Government has proved that a registrant
has committed acts inconsistent with
the public interest, a registrant must
‘‘ ‘present[] sufficient mitigating
evidence to assure the Administrator
that [he] can be trusted with the
responsibility carried by such a
registration.’ ’’ Samuel S. Jackson, 72 FR
23,848, 23,853 (DEA 2007) (quoting Leo
R. Miller, 53 FR 21,931, 21,932 (DEA
1988)). Moreover, because ‘‘past
performance is the best predictor of
future performance,’’ ALRA Labs., Inc.,
v. DEA, 54 F.3d 450, 452 (7th Cir. 1995),
this Agency has repeatedly held that
where a registrant has committed acts
inconsistent with the public interest, the
registrant must accept responsibility for
its actions and demonstrate that it will
not engage in future misconduct.
Medicine Shoppe, 73 FR 364 (DEA
2008); see Jackson, 72 FR at 23,853;
John H. Kennedy, 71 FR 35,705, 35,709
(DEA 2006); see also Hoxie v. DEA, 419
F.3d 477, 483 (6th Cir. 2005)
(‘‘admitting fault’’ is ‘‘properly
consider[ed]’’ by DEA to be an
‘‘important factor []’’ in the public
interest determination). An applicant’s
acceptance of responsibility for his prior
misconduct is a highly relevant
consideration under this factor. See
Barry H. Brooks, 66 FR 18,305, 18,309
(DEA 2001); Prince George Daniels,
D.D.S., 60 FR 62,884, 62,887 (DEA
1995); Carmel Ben-Eliezer, M.D., 58 FR
65,400, 65,401 (DEA 1993).
Specifically, Dr. Reitman candidly
admitted to his abuse from the moment
he was confronted by DEA investigators,
even admitting to abuse beyond the
Government’s proffered evidence. [FOF
12, 15, 26, 31, 35]. He cooperated in
almost every way, choosing to follow
the advice of his attorney and not to
relinquish his registration and
controlled substances until the DEA had
a warrant, but ultimately did voluntarily
surrender the controlled substances.
[FOF 17, 19, 20]. Dr. Reitman
immediately entered treatment
programs. [FOF 38, 39, 40, 43, 50, 73].
E:\FR\FM\30SEN1.SGM
30SEN1
mstockstill on DSK4VPTVN1PROD with NOTICES
60900
Federal Register / Vol. 76, No. 190 / Friday, September 30, 2011 / Notices
The Respondent presented numerous
witnesses involved in Dr. Reitman’s
rehabilitation and medical practice.
[FOF 48, 49, 57, 66, 72, 80, 85, 90].
Every witness on the topic of
rehabilitation stated that he has excelled
and is extremely committed to
overcoming his addiction. [FOF 54–55,
62, 64, 70, 77, 87]. Furthermore, he is
involved with his synagogue and has
the full support of his wife and family.
[FOF 67, 69, 70, 79]. Nine months have
passed since the day he was confronted
by the DEA, and he has not ingested or
even ordered a controlled substance
since. [FOF 28, 42].
Past DEA cases have involved
practitioners whose registrations were
either not revoked or their applications
were not denied despite more
reprehensible conduct than Dr.
Reitman’s self-prescribing. See Judy L.
Henderson, D.V.M., Grant of Restricted
Registration, 65 FR 5,672 (DEA 2000);
Jimmy H. Conway, Jr., M.D., 64 FR
32,271 (DEA 1999) (Respondent was
addicted to Lorcet and Soma and used
the names and DEA registration
numbers of his partners to order the
drug for his personal use. He candidly
admitted the abuse and began a
treatment program. The abuse occurred
in 1996, the Order to Show Cause was
issued in 1998, and the final order was
submitted in 1999. Despite felony
convictions, the Respondent was
permitted to retain his registration with
restrictions.); Robert G. Hallermeier,
M.D., 62 FR 26,818 (DEA 1997)
(Respondent was an alcoholic with
serious prescribing problems; granted a
registration with restrictions.);
Thomson, 65 FR at 75,971 (both DA and
ALJ agreed that the physician
‘‘minimized her criminal actions and
significant breaches of professional
judgment,’’ but the evidence of her
‘‘strong efforts to rehabilitate herself’’
ultimately warranted granting her a
restricted registration); John Porter
Richards, D.O., 61 FR 13,878 (DEA
1996) (Applicant had been convicted of
two felonies related to controlled
substances and subsequently sentenced
to thirty years in prison, twenty years of
which were suspended. Thereafter, the
respondent’s license to practice
osteopathic medicine was revoked
before eventually being reinstated.
However, at the application hearing in
Richards, that applicant ‘‘continued to
maintain that he had not committed the
crimes for which he had been
convicted.’’ Nonetheless, in Richards,
the DA approved the applicant’s
application without restrictions despite
the fact that, at the hearing, the
applicant accepted his conviction but
VerDate Mar<15>2010
17:19 Sep 29, 2011
Jkt 223001
did not completely admit to the crimes
for which he was convicted.). Here, Dr.
Reitman has without a doubt, readily
admitted fault and sought treatment, at
which he has thrived. [FOF 44, 54–55,
70, 77, 84, 88]. The Respondent testified
and was candid and truthful about his
past abuse. [FOF 38–47]. Thus, the
Deputy Administrator consistently
decides each case on its own merits.
This case warrants retaining a restricted
registration.
I therefore find that Dr. Reitman has
presented evidence sufficient to prove
that he can be entrusted with a DEA
Certificate of Registration.
V. Conclusion and Recommendation
I do not condone nor minimize the
seriousness of the Respondent’s prior
misconduct; however, because the
Respondent seems to be well on the
road to rehabilitation, I recommend that
Dr. Reitman be granted a registration
that restricts his handling of controlled
substances to merely prescribing and
not storing or dispensing such drugs,
and requiring that he not issue
controlled substance prescriptions to
himself or his family members. Further,
I recommend the Respondent be subject
to quarterly reporting to his local DEA
office of his prescribing of controlled
substances. I also recommend that Dr.
Reitman be ordered to consent to
unannounced inspections by DEA
personnel without requiring an
administrative inspection warrant. I
recommend these restrictions apply for
three years from the date of the final
order so directing this result. In this
way, the DEA can assure itself of the
Respondent’s compliance with DEA
regulations and of the protection of the
public interest.
Date: July 20, 2010.
Gail A. Randall,
Administrative Law Judge.
[FR Doc. 2011–25227 Filed 9–29–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 11–14]
Jack A. Danton, D.O.; Decision and
Order
On June 17, 2011, Administrative Law
Judge (ALJ) Gail A. Randall issued the
attached recommended decision.1
Thereafter, the Government filed
exceptions to the ALJ’s decision.
1 All citations to the ALJ’s decision are to her slip
opinion as originally issued.
PO 00000
Frm 00102
Fmt 4703
Sfmt 4703
Having considered the entire record
and the Government’s exceptions, I have
decided to adopt the ALJ’s decision
except for her legal conclusions with
respect to whether the Respondent
issued prescriptions for controlled
substances to several undercover
officers and several of her findings
under factor five. However, because I
otherwise agree with the ALJ’s findings
as to the public interest factors, I adopt
her ultimate conclusion that the
Government has shown that
‘‘Respondent’s continued registration
would not be in the public’s interest’’
and that the Respondent ‘‘has not
accepted responsibility for all of her
wrongdoing, nor has she adequately
assured this tribunal of future
compliance.’’ ALJ at 64. I will therefore
order that Respondent’s registration be
revoked and that any pending
application be denied.
The Government’s Exceptions
The ALJ concluded that the
Government failed to establish that
Respondent’s prescriptions to three
undercover officers (UC) lacked a
legitimate medical purpose. ALJ at 42–
51; see also 21 CFR 1306.04(a) (‘‘A
prescription for a controlled substance
* * * must be issued for a legitimate
medical purpose by an individual
practitioner acting in the usual course of
his professional practice.’’). In so
concluding, the ALJ explained that the
Government ‘‘provided no expert
testimony to support this finding,’’ and
that while the Government ‘‘introduced
the transcripts and recordings of the
undercover transactions, and a summary
of those transactions via officer
testimony[,] * * * the Government ha[d]
provided no meaningful lodestar by
which this court can measure the
legitimacy of the Respondent’s medical
practice under Florida statutory and
regulatory requirements.’’ Id. at 43. The
ALJ noted that ‘‘while the [A]gency has
considered over fifty cases concerning
the legitimacy of a practitioner’s
prescriptions since [Gonzales v. Oregon,
546 U.S. 243 (2006)], the [A]gency has
seldom found a violation of 21 CFR
1306.04(a) absent expert testimony[,]’’
and that ‘‘where the [A]gency has found
such illegitimacy without an expert’s
testimony, that finding was based on
patent violations, where diversion was
either unrefuted or unquestionable.’’ Id.
at 43–44 (citing cases).
The ALJ also noted that ‘‘expert
testimony may not be required’’ where
the evidence shows that a registrant
‘‘has acted in a manner that clearly
contravened state law governing what
constitutes a legitimate medical
practice,’’ such as where a physician
E:\FR\FM\30SEN1.SGM
30SEN1
Agencies
[Federal Register Volume 76, Number 190 (Friday, September 30, 2011)]
[Notices]
[Pages 60889-60900]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-25227]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 09-65]
Stephen L. Reitman, M.D.; Decision and Order
On July 20, 2010, Administrative Law Judge Gail A. Randall issued
the attached recommended decision.\1\ Neither party filed exceptions to
the ALJ's decision.
---------------------------------------------------------------------------
\1\ All citations to the ALJ's decision are to the slip opinion
as issued by her.
---------------------------------------------------------------------------
Having reviewed the entire record, I have decided to adopt the
ALJ's rulings, findings of fact, conclusions of law,\2\ and recommended
order except as discussed below. Accordingly, while Respondent's
registration will be continued, I conclude that the record requires
that several conditions be placed on it to adequately protect the
public interest.
---------------------------------------------------------------------------
\2\ The ALJ found that Respondent violated California law by
obtaining controlled substances from a distributor ``while
concealing the fact that he was dispensing to himself.'' ALJ at 33
(citing Cal. Health & Safety Code 11173). The ALJ did not, however,
cite any decisional law holding that conduct similar to that engaged
in by Respondent violates this provision. See id. Moreover, there is
no evidence establishing that Moore Medical required Respondent to
make any disclosure as to his purpose in purchasing the drugs. Cf.
Lovejoy v. AT&T Corp., 92 Cal.App.4th 85, 96 (2001) (noting that
tort of concealment requires that ``the defendant must have been
under a duty to disclose the fact to the plaintiff''). I therefore
do not adopt this finding. However, the evidence does establish the
other violations of the CSA and State law as discussed by the ALJ.
---------------------------------------------------------------------------
At the time of the hearing, the Medical Board of California (MBC)
had filed an accusation against Respondent. ALJ at 31. However, the MBC
did not issue a final decision in the matter until December 20, 2010,
which became effective on January 19, 2011. In re Stephen Lee Reitman,
M.D., Decision at 1 (Cal. Med. Bd. Dec. 20, 2010). I take official
notice of the MBC's Decision and the Stipulated Settlement and
Disciplinary Order.\3\ Therein, the Board revoked Respondent's medical
license but stayed the revocation and placed him on probation for five
years subject to numerous conditions. Stipulated Settlement, at 4. The
conditions include, inter alia, that Respondent ``maintain a record of
all controlled substances ordered, prescribed, dispensed, administered,
or possessed by'' him, that he abstain ``from the personal use or
possession of controlled substances'' except as ``to medications
lawfully prescribed to [him] by another practitioner for a bona fide
illness or condition'' and that he ``notify the Board'' within fifteen
calendar days of receiving any such prescription, and that he take both
a prescribing practices course and an ethics course. Id. at 4-10.
---------------------------------------------------------------------------
\3\ Under the Administrative Procedure Act (APA), an agency
``may take official notice of facts at any stage in a proceeding-
even in the final decision.'' U.S. Dept. of Justice, Attorney
General's Manual on the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). In accordance with the APA and
DEA's regulations, Respondent is ``entitled on timely request, to an
opportunity to show to the contrary.'' 5 U.S.C. 556(e); see also 21
CFR 1316.59(e). Respondent can dispute the facts of which I take
official notice by filing a properly supported motion for
reconsideration within twenty days of service of this Order, which
shall begin on the date it is mailed.
---------------------------------------------------------------------------
Most significantly, the Order requires that Respondent, at his own
expense, ``contract with a laboratory or service--approved in advance
by the Board or its designee--that will conduct random, unannounced,
observed, urine testing a maximum of four times each month.'' Id. at 5.
Moreover, ``[t]he contract shall require results of the urine tests to
be transmitted by the laboratory or service directly to [the] Board or
its designee
[[Page 60890]]
within four hours of the results becoming available'' and that
Respondent's ``[f]ailure to maintain this laboratory or service during
the period of probation is a violation of [his] probation.'' Id. at 5-
6. Finally, the Order provides that it is a violation of Respondent's
probation if he ``[f]ail[s] to submit to or comply with the time frame
for submitting to, or fail[s] to complete the required biological fluid
testing.'' Id. at 5-6.
In her decision, the ALJ rejected the Government's contention that
Respondent's registration should be revoked because he has been sober
for only eleven months and that this is an insufficient period to
demonstrate that he is not likely to relapse. ALJ at 35 (citing Gov.
Br. at 9-10). In so ruling, the ALJ reasoned that ```[t]he paramount
issue is not how much time has elapsed since [the Respondent's]
unlawful conduct, but rather, whether during that time [the] Respondent
has learned from past mistakes and has demonstrated that he would
handle controlled substances properly if entrusted with a DEA
registration.''' Id. (quoting Leonardo v. Lopez, M.D., 54 FR 36915
(1989)). However, none of the cases which have invoked this principle
involved circumstances similar to those at issue here, where, a
registrant has abused controlled substances for seven years and has
demonstrated his sobriety for only one year. See Lopez, 54 FR 36915;
see also Robert L. Dougherty, M.D., 76 FR 16823 (2011); Robert A.
Leslie, M.D., 64 FR 25908 (1999); Mary M. Miller, M.D., 63 FR 71157
(1998); John Porter Richards, D.O., 61 FR 13878 (1996); James W. Shore,
M.D., 61 FR 6262 (1996).
That being said, I agree with the ALJ's findings that Respondent
has accepted responsibility for his misconduct and that he has
undertaken substantial efforts at rehabilitation. Indeed, even the
Government acknowledges that Respondent had taken ``various and
comprehensive steps * * * toward rehabilitation'' and that his efforts
were ``entered into voluntarily, which no doubt demonstrates a
commitment to staying clean and sober.'' Gov. Br. at 9. However, as the
Government noted in its brief, according to the evidence adduced at the
hearing, under the terms of Respondent's contract with his treatment
program, the program is not obligated to report any relapse to either
the MBC or this Agency.\4\ Id; see also Tr. 91. Given the limited time
for which Respondent has demonstrated his sobriety (on the record of
the hearing), such an arrangement is manifestly inadequate to support
the continuation of a registration. Thus, I am not persuaded by the
ALJ's reasoning that ``under the particular circumstances of this case,
nine months is not such a short recovery period that it should serve as
grounds for revocation.'' ALJ at 36.
---------------------------------------------------------------------------
\4\ Respondent did not introduce into evidence a copy of his
treatment contract.
---------------------------------------------------------------------------
However, as found above, subsequent to the closing of the record,
Respondent entered into a Stipulated Settlement and Disciplinary Order
with the MBC which provides for random biological fluid testing and
which requires that the results be reported directly to the MBC.
Moreover, since the record closed, additional time has passed during
which Respondent has been subject to random biological fluid testing,
and during this period, no evidence of a relapse has been presented to
this Office.
These developments, when considered along with Respondent's strong
showing as to his acceptance of responsibility, his efforts at
rehabilitation, as well as the lack of evidence that he harmed anyone
other than himself or diverted drugs to others, supports the conclusion
that Respondent's continued registration would not ``be inconsistent
with the public interest.'' \5\ 21 U.S.C. 823(f). Accordingly,
Respondent's pending renewal application will be granted. However, to
adequately protect the public interest, Respondent's registration will
be subject to the conditions set forth below, which shall remain in
effect until the same date as the State's probation expires. Any
violation of these conditions constitutes an act which renders his
registration ``inconsistent with the public interest,'' 21 U.S.C.
824(a)(4), and subject to proceedings under that provision.
---------------------------------------------------------------------------
\5\ In her discussion of whether Respondent had accepted
responsibility, the ALJ explained that ``[p]ast DEA cases have
involved practitioners whose registrations were either not revoked
or their applications were not denied despite more reprehensible
conduct than [Respondent's] self-prescribing.'' ALJ at 37. While I
agree that in Judy L. Henderson, 65 FR 5672 (2000), and Mary
Thomson, M.D., 65 FR 75969 (2000), the registrants committed acts
which are arguably more egregious than those committed by
Respondent, I do not see any meaningful difference between the
conduct committed by the registrant in Jimmy H. Conway, Jr., M.D.,
64 FR 32271 (1999), and Respondent. As for her discussion of Robert
G. Hallermeier, M.D., 62 FR 26818 (1997), suffice it to say that
were a case with similar facts presented to me, that individual
would receive a sanction that more appropriately reflected the grave
harm which that registrant caused the public and the Agency's
interest in deterring similar misconduct. See Joseph Gaudio, M.D.,
74 FR 10083, 10094 (2009) (citing Southwood Pharmaceuticals, Inc.,
72 FR 36487, 36504 (2007)). See also Butz v. Glover Livestock
Commission Co., Inc., 411 U.S. 182, 187-88 (1973).
Finally, the ALJ's discussion that the applicant in John Porter
Richards, D.O., 61 FR 13878 (1996), ``continued to maintain that he
had not committed the crimes for which he had been convicted,'' ALJ
at 38, is simply a misreading of that decision. As the decision
makes clear, the text quoted by the ALJ was a paraphrase of a
question posed of the applicant by the Government on cross-
examination. See 61 FR at 13879 (``When asked on cross-examination
whether, consistent with his not guilty plea, he continued to
maintain that he had not committed the crimes for which he had been
convicted, the Respondent testified, ``I accept my conviction[.]'').
When the Government then asked ``to what extent he did so,'' the
applicant testified: ```In its completeness.''' Id. Notably, the
decision contains no further discussion suggesting that the
applicant acknowledged his conviction but then denied having
committed the crime or claimed that he was set up.
---------------------------------------------------------------------------
(1) Respondent's registration is restricted to authorizing the
prescription of controlled substances. Respondent shall not prescribe
controlled substances to himself or any family members. Respondent is
further prohibited from obtaining controlled substances from a
manufacturer, distributor, or pharmacy, whether the controlled
substances are obtained by ordering them from a manufacturer,
distributor, or pharmacy, or provided to him by a manufacturer,
distributor, or pharmacy as a sample. This condition does not prohibit
Respondent from obtaining a prescription for a controlled substance
from another practitioner for a legitimate medical condition and
filling such a prescription at a pharmacy.
(2) Respondent shall maintain a log of all controlled substance
prescriptions he issues. Respondent shall provide a copy of his log
each quarter to the local DEA office within ten business days of the
end of each quarter of the calendar year (i.e., March 31st; June 30th;
September 30th, and December 31st). If Respondent issues no controlled
substance prescriptions during the quarter, a report indicating that no
prescriptions were issued must also be filed no later than ten business
days following the end of the quarter.
(3) Respondent shall consent to unannounced inspections of his
registered location by DEA personnel and waives his right to require
that Agency personnel obtain an Administrative Inspection Warrant prior
to conducting an inspection of his registered location.
(4) Any violation of the probationary terms imposed pursuant to the
MBC's requirement that he contract with a laboratory or service to
provide for random biological fluid testing shall constitute grounds
for the immediate suspension of his DEA registration.
[[Page 60891]]
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f) and
824(a)(4), as well as 28 CFR 0.100(b), I order that the application of
Stephen L. Reitman to renew his DEA Certificate of Registration be, and
it hereby is, granted subject to the conditions set forth above. This
Order is effective immediately.
Dated: September 20, 2011.
Michele M. Leonhart,
Administrator.
Christine M. Menendez, Esq. for the Government.
Robert C. Schlein, Esq. for the Respondent.
Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision
of the Administrative Law Judge
I. Procedural Background
Gail A. Randall, Administrative Law Judge. The Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration (``DEA'' or ``Government''), issued an Order to Show
Cause (``Order'') dated September 10, 2009, proposing to revoke the DEA
Certificate of Registration Number AR6012568, of Stephen L. Reitman,
M.D. (``Respondent'' or ``Dr. Reitman''), as a practitioner, pursuant
to 21 U.S.C. 824(a)(4), and deny any pending applications for renewal,
modification, or additional registrations, pursuant to 21 U.S.C.
823(f), because the continued registration of the Respondent is
inconsistent with the public interest, as that term is defined in 21
U.S.C. 824(a)(4). [Administrative Law Judge Exhibit (``ALJ Exh.'') 1].
On September 25, 2009, the Respondent, through counsel, filed a
request for a hearing in the above-captioned matter. [ALJ Exh. 2].
The hearing was held in San Diego, California, on April 13-14,
2010. [ALJ Exh. 4 at 1; Transcript (``Tr.'') Vol. I-II]. At the
hearing, Counsel for the DEA and Counsel for the Respondent called
witnesses to testify and introduced documentary evidence. After the
hearing, both parties submitted Proposed Findings of Fact, Conclusions
of Law and Argument.
II. Issue
The issue in this proceeding is whether or not the record as a
whole establishes by a preponderance of the evidence that the Drug
Enforcement Administration should revoke the DEA Certificate of
Registration Number AR6012568 of Stephen L. Reitman, M.D., as a
practitioner pursuant to 21 U.S.C. 824(a), and deny any pending
applications to renew or modify this registration under 21 U.S.C.
823(f), because to continue Respondent's registration would be
inconsistent with the public interest as that term is used in 21 U.S.C.
823(f). [ALJ Exh. 3 at 1; Tr. 5].
III. Findings of Fact
I find, by a preponderance of the evidence, the following facts:
A. Background
1. Respondent is registered with DEA as a practitioner in Schedules
II-V pursuant to DEA Registration Number AR6012568. [ALJ Exh. 3 at 1;
Government Exhibit (``Govt. Exh.'') 1; Tr. 58].
2. Respondent is licensed as a physician and surgeon in the State
of California pursuant to License Number G25924. Respondent's licensure
status is renewed and current. [ALJ Exh. 3].
3. Dr. Reitman attended the University of Illinois in Champaign for
undergraduate school. Then he studied at the University of Illinois
Medical School in Chicago from 1965 to 1969. Dr. Reitman graduated
medical school in 1969. [Tr. 55]. He next attended the University of
Cincinnati for internship and residency from about 1969 until 1972.
From there, he studied at Ann Arbor University of Michigan from 1972
until 1974 for a fellowship in nephrology. In 1974, he and his wife
moved to San Diego where he has been in practice since that time. He
has been licensed to practice medicine in California since 1973.
[Respondent's Exhibit (``Resp. Exh.'') 5; Tr. 55-56].
4. Dr. Reitman is currently working in La Mesa, California. His
practice consists mostly of geriatric and internal medicine treating
senior citizens, people 60 or older. He sees maybe 15 to 20 patients
per day. [Tr. 57]. In his practice, he sees many seniors with chronic
pain. He prescribes Vicodin, codeine, and Darvocet, as well as anti-
anxiety medications and anti-depressants. He does not dispense. [Tr.
58-59].
B. DEA Investigation
5. Diversion Investigator Ayoma Rudy (``Investigator Rudy'') has
been a diversion investigator with the DEA in San Diego, California
since November 3, 2005. [Tr. 18-19]. Prior to becoming a diversion
investigator, she was a DEA group assistant in 1996. [Tr. 19]. She then
became an investigative assistant in approximately 2001. [Id.]. She
trained for three months at Quantico, where she received specialized
training including how to conduct regulatory, financial, and criminal
investigations and how to write reports, take affidavits, conduct
search warrants, and conduct interviews. [Tr. 20]. Investigator Rudy is
now responsible for investigating the illegal diversion of controlled
substances and listed chemicals. She is the lead investigator of the
issues surrounding the Dr. Reitman case. [Tr. 20-22].
6. Investigator Rudy began investigating Dr. Reitman on May 28,
2009, when Moore Medical submitted a controlled substance report to the
San Diego Field Division showing what the DEA considered to be
excessive purchases of controlled substances by Dr. Reitman from Moore
Medical. [Govt. Exh. 3, 5; Tr. 23]. A DEA registrant has a
responsibility to inform the DEA of any excessive purchases or
suspicious orders. [Tr. 26]. Investigator Rudy's supervisor, John
Partridge, told her to follow up on these purchases, because he
considered them excessive. [Tr. 26-27].
7. A Controlled Substance Utilization Review (``CURES'') report is
generated by a California Department of Justice database, which tells
an investigator what the patient filled, what drugs the patient filled,
when, which pharmacies the patient went to, and how many doctors the
patient saw within the week or within the day. [Tr. 22].
8. In the case of the report from Moore Medical, the DEA
Certificate of Registration Number used to order the controlled
substances was AR6012568, which is Dr. Reitman's number. [Govt. Exh. 3;
Tr. 25].
9. Dr. Reitman was ordering Butalbital APAP (acetaminophen)
Caffeine with codeine \6\ and APAP 300mg with codeine 60mg from January
2005 through March 18, 2009. [Govt. Exh. 5; Tr. 27-8]. APAP with
codeine is a Schedule V controlled substance. [Tr. 28]. Butalbital APAP
with Codeine is a Schedule III controlled substance. [Tr. 28].
---------------------------------------------------------------------------
\6\ The milligrams are not specified for this drug. [See Govt.
Exh. 5].
---------------------------------------------------------------------------
10. On July 8, 2009, DEA Diversion Investigators Ayoma Rudy and
Kenneth Crouch interviewed Dr. Reitman regarding controlled substances
that he purchased from Moore Medical. [ALJ Exh. 3 at 2; Tr. 28].
11. At that time, Dr. Reitman invited them in, asked them to sit
down. [Tr. 29]. Investigator Rudy stated that Dr. Reitman was friendly,
cooperative and forthright. [Tr. 41-42]. He seemed coherent and
rational. [Tr. 42].
12. Dr. Reitman admitted that the report from Moore Medical was
correct. [Tr. 30]. He admitted to having an addiction problem. [Tr.
42]. During the
[[Page 60892]]
interview, Dr. Reitman stated that he ordered the substances in
question for his personal use and that he was not selling the
controlled substances or exchanging them for other services. [ALJ Exh.
3 at 2; Tr. 30, 32]. Investigator Rudy said, ``By the third sentence,
he put his head down'' and said that he ``ordered [the controlled
substances] for personal use.'' [Tr. 30]. Dr. Reitman repeatedly stated
that he needs help. [Tr. 32].
13. At that time, Dr. Reitman kept the controlled substances in a
locked cabinet at his office location, the contents of which he showed
to the two Diversion Investigators. [ALJ Exh. 3 at 2; Tr. 31-32]. He
opened the cabinet, and DI Rudy could see about 22 or 23 bottles of the
Butalbital and the APAP with codeine. [Tr. 31]. Dr. Reitman told DI
Rudy that he was storing the controlled substances at his office,
because he did not want his wife to find out. [Tr. 32].
14. Dr. Reitman stated that he had no records (receipts, invoices,
log, or dispensing records) related to the controlled substances in
Moore Medical's report. [Tr. 30-31].
15. Investigator Rudy asked him if he was trading or selling the
drugs, and Dr. Reitman said no. [Tr. 32]. DI Rudy also stated that she
believed his explanation. [Tr. 47-48]. At this hearing, Dr. Reitman
stated that the drugs were for his personal use. He never sold them or
dispensed them to anybody. [ALJ Exh. 3 at 2; Tr. 81].
16. Investigator Rudy asked the Respondent if he realized that he
was violating DEA policy, and he said yes. [Tr. 32].
17. At that point, Investigator Rudy left without conducting an
inventory, because she wanted to report this unique situation to her
supervisor. [Tr. 33, 46]. Investigator Rudy had no way of conducting an
inventory, because Dr. Reitman had no records to compare with the
number of pills on hand. [Tr. 46, 47]. Her supervisor told her to seek
a voluntary surrender of both his registration and the controlled
substances, which she did. [Tr. 33, 45]. However, Dr. Reitman refused
to voluntarily surrender the controlled substances or his registration
until after he had spoken with his attorney. [Tr. 33, 45]. Investigator
Rudy stated that she did not think it was unusual for Dr. Reitman to
want to speak to an attorney and that he had a right to do so. [Tr. 43-
44].
18. However, Investigator Rudy did tell Dr. Reitman to keep the
controlled substances locked in the cabinet. [Tr. 41].
19. On July 13, 2009, DI Rudy returned to Dr. Reitman's office,
this time with a different investigator, Investigator Theresa Grant, to
seek a voluntary surrender of his registration. [Tr. 34-5]. Dr.
Reitman, acting pursuant to the advice of his attorney, refused to
surrender both the controlled substances and his DEA Certificate of
Registration to DEA Diversion Investigators Rudy and Grant. [ALJ Exh. 3
at 2; Tr. 35].
20. On July 15, 2009, Investigator Rudy again met with Dr. Reitman
at his office. [Tr. 35]. On this occasion, she was accompanied by
Special Agent Rockwell Herron. [Tr. 35]. Dr. Reitman voluntarily
surrendered the controlled substances in question to Investigator Rudy
and Special Agent Herron. [ALJ Exh. 3 at 2; Tr. 35-36]. Investigator
Rudy seized the controlled substances and gave Dr. Reitman a receipt
(DEA-12) for the drugs. [Tr. 36, 41, 44].
21. Investigator Rudy and Agent Herron seized the Butalbital and
the APAP with codeine, which were being stored in the same locked
cabinet. [Tr. 36].
22. Investigator Rudy seized four sealed bottles and one partial
bottle of APAP with codeine. [Tr. 36]. These drugs were in both 500-
and 100-count bottles. [Tr. 47].
23. Investigator Rudy seized eight sealed bottles and one partial
bottle of Butalbital with codeine. [Tr. 36-37]. These drugs were in
100-count bottles. [Tr. 47].
24. Investigator Rudy stated there was a significant difference
between what was seized and the amount ordered according to the Moore
Medical records. She is unsure of the amount that was in fact seized.
[Tr. 47, 48-49]. She stated that he ordered 128 bottles of Butalbital
and 32 bottles of APAP with codeine. However, there were only eight
bottles of Butalbital and four bottles of APAP with codeine. [Tr. 48-
9]. Investigator Rudy could not provide a specific number of the amount
of pills he had on hand. [Tr. 49-50]. Therefore, Dr. Reitman had at
least 800 dosage units of each controlled substance on hand at this
time.
25. Investigator Rudy took these drugs to the San Diego Field
Division's evidence room. They are now at the Southwest Lab in Vista,
San Diego. [Tr. 37].
26. Investigator Rudy stated that Dr. Reitman told her that he was
taking three to six pills per day. [Tr. 53].
27. Sometime in August, Investigator Rudy received an updated
report from Moore Medical, which contained information related to
controlled substances purchased by Dr. Reitman from Moore Medical from
March 19, 2009 through August 27, 2009. [Govt. Exh. 4; Tr. 38, 39]. She
received this report from Tracy Lofquist from Moore Medical's
Regulatory Affairs department. [Tr. 38]. Again, this document shows
that Dr. Reitman ordered Butalbital APAP with codeine and APAP with
codeine. [Tr. 39]. Patrick Early, Vice President of Regulations and
Operational Affairs at Moore Medical tallied Dr. Reitman's orders of
controlled substances from January 1, 2005, through August 27, 2009.
[Govt. Exh. 5 at 2-3]. He stated that Dr. Reitman ordered 11,600 dosage
units of APAP with Codeine and 12,800 dosage units of Butalbital APAP
Caffeine with Codeine in that time (which is four years, seven months,
and twenty-seven days, or seventeen-hundred days). However, since
Investigator Rudy seized at least 800 dosage units of APAP with Codeine
and another 800 dosage units of Butalbital APAP Caffeine with Codeine,
Dr. Reitman could have only ingested approximately 10,800 dosage units
of APAP with Codeine and approximately 12,000 dosage units of
Butalbital APAP with Codeine during that time. [Compare Govt. Exh. 5 at
2-3 with Tr. 36-37, 47]. This is an approximate average of six APAP
with Codeine per day and an average of seven Butalbital APAP Caffeine
with Codeine per day for a maximum total of thirteen pills per day.
[Govt. Exh. 5 at 2-3].
28. Dr. Reitman's last order was placed on May 22, 2009. He has not
ordered any controlled substances from Moore Medical since. [Govt. Exh.
4; Tr. 39-40, 44]. The DEA's ARCOS database, which stands for Automated
Reporting and Consolidated Ordering System, tracks controlled
substances orders. [Tr. 40]. Investigator Rudy used ARCOS to confirm
that Dr. Reitman has made no controlled substances orders since May 22,
2009. [Tr. 40].
29. Dr. Reitman still has the ability to order controlled
substances. [Tr. 40, 88]. He has not ordered any, but he has prescribed
controlled substances to his patients. [Tr. 88].
30. Dr. Reitman stated that, other than an action related to the
events that led to this hearing, Dr. Reitman has only had one prior
interaction with the Medical Board of California. [Tr. 81-2]. The
Medical Board of California placed Dr. Reitman on probation from 2002
until 2004, because he lost a malpractice case and the Board felt he
had improperly treated a patient. The Board has taken no other action
on his medical license. [Tr. 56-57, 101-02]. The 2002 probation had
nothing to do with his abuse of codeine. [Tr. 102].
[[Page 60893]]
C. Dr. Reitman's Addiction
31. Dr. Reitman stated that he considers himself to be a recovered
drug addict. He admits to abusing controlled substances, stating that
he began to abuse Butalbital with codeine and APAP with codeine in
about 2002 or 2003. Initially, he was prescribed these drugs by his
private physician to treat headaches. Then, when he was at the point
that he was taking more than 100 per month, he began ordering them for
himself from Moore Medical. [Tr. 59-60, 77].
32. Dr. Reitman stated that he began getting essentially migraine
headaches when he was about five or six years old. [Tr. 77]. They
abated until the late 1990s when he was suffering from cervical
stenosis and neck pain. [Tr. 78].
33. The Respondent admits that he knew that he ``was taking an ever
larger dose of medication,'' but that he needed the medication because
he was having the headaches. Dr. Reitman stated, ``I was stupid at the
time. I probably should have asked to go to a rehab program or
something to get myself off it at that time. I just didn't. I made a
tremendous mistake.'' [Tr. 87].
34. Since July of 2009, Dr. Reitman has had few headaches, and he
is able to treat these headaches with Imitrex or ibuprofen. [Tr. 78].
Dr. John E. Milner told Dr. Reitman that these headaches are codeine
withdrawal headaches that may last from 18 to 24 months. [Tr. 78].
Also, Butalbital is a barbiturate. [Tr. 103]. However, Dr. Milner told
Dr. Reitman that he did not think that Dr. Reitman was ever addicted to
Butalbital, just the codeine. [Tr. 104]. Today, if he needs a
controlled substance, he has two physicians, a neurologist and a
primary physician, who can prescribe that for him. [Tr. 79].
35. Dr. Reitman candidly admitted that the Moore Medical report
does not paint a clear picture of his self-prescribing practices. [Tr.
60-61]. The document begins with purchases on March 8, 2005. However,
the Respondent admits to ordering for himself from Moore Medical since
approximately 2002. [Tr. 60-61]. He stated that prior to 2002, he had
been receiving his prescriptions from his private physician for about
two years. [Tr. 61]. Dr. Reitman also stated that the Moore Medical
report reflects all of the kinds of controlled substances he purchased
from Moore Medical. [Tr. 81]. He did not purchase controlled substances
from any other distributor. [Tr. 63].
36. Dr. Reitman said that he increased the amount of drugs that he
was taking to the point that he was ingesting between eight and twelve
(approximately 660 mg) per day. [Tr. 61-63].
37. Dr. Reitman states that he kept no records from Moore Medical.
[Tr. 63-64]. He states he has no dispensing log, because he didn't
dispense to anyone but himself. [Tr. 64].
D. Dr. Reitman's Treatment
1. Dr. Stephen Reitman
38. Dr. Reitman stated that he does not remember telling
Investigator Rudy about his problem, but that he did tell Dr. William
Friedel on the night of July 8, 2009. Dr. Friedel recommended he speak
with an attorney and attend a meeting of the Physician Well-Being
Committee at Grossmont Hospital, which occurs once every three months
and happened to be the next day, July 9, 2009. Dr. Reitman attended the
Well-Being Committee meeting where he told Dr. Calaprete of his drug
problem. [Tr. 64-65, 68, 69, 102-03]. He continues to attend these
committee meetings. [Tr. 69, 73].
39. Dr. Friedel also told Dr. Reitman about a diversion program.
[Tr. 64-65, 74]. Dr. Reitman has also signed a Pacific Assistance Group
(``PAG'') contract with Duane Rogers which ``spells out what I will do
and what will happen to me if I am found to be positive of substances
or alcohol.'' [Tr. 74, 89]. He has to not abuse controlled substances,
attend diversion meetings twice a week, and allow random urine tests
for a minimum of four to five times per month for three years. [Tr. 74,
90]. All of his urine tests have been negative since he began the
program in July of 2009. [Tr. 74, 90]. He hasn't missed any meetings,
but has been excused from a few when he was out of town. [Tr. 90-91].
If he breaks a term of the contract, he can be told that he cannot go
to work until he has had two negative urine tests. [Tr. 91]. However,
if he violates a term of this contract, it is not reported to the
California Medical Board or to the DEA. [Tr. 91].
40. Dr. Reitman also attends Alcoholics Anonymous (``AA'')
meetings. [Tr. 75]. He completed a 90 in 90 program, which means going
to a minimum of 90 meetings in 90 days. Now, he attends AA meetings two
to three times a week and meets with his sponsor, Philip Shapiro, on
the phone or in person once per week. [Tr. 75]. Dr. Reitman attends AA
meetings instead of Narcotics Anonymous (``NA'') meetings, because he
did not feel comfortable at NA meetings. He said the participants were
all younger, 17 to 30 years old and used four-letter words. Many had
been to prison. [Tr. 76]. Several people at the AA meetings are also
substance abusers or poly-drug abusers. [Tr. 76].
41. With regards to his addiction to controlled substances, Dr.
Reitman also told two of his children who live in the area and his wife
the following Monday when she returned from a trip abroad. [Tr. 67-68].
However, he did not admit to anyone that he had a problem until he was
confronted by Investigator Rudy. [Tr. 65-66].
42. The last time he ingested a controlled substance was on the
morning of July 8, 2009, when he took two tablets of the 60 mg Tylenol
with codeine and two tablets of the Butalbital with codeine. He has
since been substance free for over nine months. [Resp. Exh. 3 at 1; Tr.
66, 71].
43. On August 3, 2009, Dr. Reitman voluntarily entered an inpatient
program at Rancho L'Abri in the East County of San Diego for 30 days.
[Resp. Exh. 1, 2, 3; Tr. 70, 71, 72]. The program is run by Dr. John
Milner. [Tr. 71]. Dr. Reitman conducted a five-day detoxification
period at home prior to entering the program at Rancho L'Abri. [Tr.
72]. Through the program, Dr. Reitman learned that while he was self-
prescribing codeine, he was most likely experiencing more headaches as
a result of daily codeine withdrawal. [Tr. 73]. He states he has had no
desire to take codeine since he stopped and that he feels like a
different person. [Tr. 73, 79]. Though he still gets some headaches, he
states that they are the result of ongoing changes in the mind and body
resulting in his cessation of using codeine. [Tr. 88-89].
44. The Respondent stated that he has had a 100% recovery and that
he is 100% committed to sobriety. [Tr. 80, 88]. When asked, he stated,
``Definitely. I never want to go backwards.'' [Tr. 80]. However, he
also notes that it is a continuing thing and chemical dependency is
something that he has to be worried about for the rest of his life,
which is why he states that he will continue to go to AA meetings. [Tr.
88]. Dr. Reitman also states that though he abused codeine for eight
years and has only been clean for a little over nine months, he is well
on the road to recovery, and in more than just the early stages. [Tr.
89].
45. The Respondent offered into evidence approximately 18 patient
comments about Dr. Reitman from August 1, 2009, to December 31, 2009,
and from January 1, 2010, to March 23, 2010. [Resp. Exh. 9; Tr. 92-93].
The comments are mostly positive other than a few typical criticisms.
[Resp. Exh. 9 at 2]. Additionally, during the time that he was addicted
to codeine,
[[Page 60894]]
Dr. Reitman said that he did not receive any patient complaints. [Tr.
102].
46. The Respondent offered into evidence a Letter of Compliance
from Duane Rogers, Psy.D., MFT, dated March 27, 2010.\7\ [Resp. Exh. 7;
Tr. 95-6]. Therein, Dr. Rogers states that Dr. Reitman ``has fully
participated and complied with the physicians monitoring program from
the above date [ ] as a self-referred voluntary participant.'' [Resp.
Exh. 7]. The letter also states: ``To date, all tests are negative for
all drugs of abuse and alcohol.'' [Id.].
---------------------------------------------------------------------------
\7\ Although the letter is dated March 27, 2009, the parties
agreed that this was a typographical error and the actual date was
March 27, 2010. [Tr. 95-96].
---------------------------------------------------------------------------
47. The Respondent also offered into evidence the office notes from
a neurologic evaluation of Dr. Reitman by Dr. Boris Khamishon, Dr.
Reitman's treating neurologist who has been helping him with his
headaches. [Resp. Exh. 8; Tr. 96-7].
2. Dr. Peter Colaprete
48. Dr. Peter Colaprete is a physician at Grossmont Hospital. [Tr.
108-9]. He began working with Dr. Reitman in 1987. [Tr. 109]. He has
known Dr. Reitman for 23 years and considers him to be a friend. [Tr.
113]. Dr. Colaprete has an undergraduate degree in biology and
chemistry. He then attended medical school, after which he completed a
residency in emergency medicine, a fellowship in critical care
medicine, and another residency in hyperbaric medicine. [Tr. 108].
49. Dr. Colaprete has been the chairman of the Grossmont Hospital
Wellness Committee for approximately ten years, and has been a member
of the committee for approximately twenty years. [Tr. 109]. The
committee was mandated by the State of California in the 1970s with the
purpose of helping physicians that are addicted to medications or
alcohol or are suffering from dementia or psychiatric illness. [Tr.
109-10]. Prior to the establishment of these types of committees,
doctors such as Dr. Reitman might have simply lost their license. This
is a way to allow troubled doctors to continue to practice if the
committee and the State feel that this is an option. There are ten
members on the committee, and all have been there for more than five
years. [Tr. 114]. At least one member of the committee has to have been
a physician with a former addiction problem. [Tr. 119]. The committee
meets quarterly, conducts random urine screens, and establishes a
contract with the doctors that must be followed. The committee also
stays in contact with the doctors as well as their physicians. [Tr.
114-15, 116]. The physician usually must attend these meetings for two
or three years. [Tr. 116, 118].
50. In approximately July of 2009, it came to Dr. Colaprete's
attention that Dr. Reitman would need the assistance of the Wellness
Committee. [Tr. 110]. Dr. Reitman has attended three meetings since
that time. [Id.]. Dr. Reitman told the committee of his recurring
headaches, his treatment of those headaches, and his subsequent self-
prescribing of codeine in large amounts. [Tr. 111].
51. Dr. Colaprete stated that the committee has not done any
urinalysis tests for Dr. Reitman. [Tr. 115].\8\ As part of the
contract, twice per month, Dr. Reitman has to meet with a clinical
psychologist, Duane Rogers, who can also do screening. [Id.].
---------------------------------------------------------------------------
\8\ However, Duane Rogers has been conducting urinalysis tests
and all have been negative for drugs ``of abuse'' and alcohol.
[Resp. Exh. 7]. Rancho L'Abri also conducted urinalysis tests, which
have all been negative as well. [Resp. Exh. 4].
---------------------------------------------------------------------------
52. If the Committee feels that the physician should not be
permitted to work (i.e. the doctor fails to attend a meeting, tests
positive on a urinalysis, admits to a relapse, etc.), then they can
recommend this to the hospital's chief of staff who can summarily stop
that physician from working. [Tr. 115-16, 117]. This would also be
reported to the Medical Board of California, but not the DEA. [Tr. 117,
124].
53. Dr. Colaprete is familiar with Dr. Milner, the director of the
Rancho L'Abri program. [Tr. 111-12]. Dr. Colaprete stated that Dr.
Milner is very knowledgeable in prescription drugs and has seen many,
many patients. [Tr. 112].
54. With regards to Dr. Reitman's recovery, Dr. Colaprete stated
that Dr. Reitman was their ``star physician.'' Dr. Colaprete also said,
``He completed the program as we requested. He's followed all our
instructions. He's come to every meeting we've asked him to come to,
and, again, I've had, you know scores of physicians that have been
requested to come to the committee, and I believe Dr. Reitman is at the
top of that list of people that have completed and have performed as we
requested.'' [Tr. 112-13]. Dr. Colaprete stated he intends to have Dr.
Reitman continue to participate in this program. [Tr. 113].
55. In twenty years on the committee, Dr. Colaprete has seen
approximately twenty physicians with substance abuse problems. [Tr.
118]. He has never seen a physician relapse who seemed very committed
to recovery. [Tr. 119]. He also stated that having access to drugs as
well as the ability to write prescriptions could potentially be a
problem. [Tr. 120]. However, when asked if he would characterize Dr.
Reitman as being recovered, Dr. Colaprete stated, ``* * * he's pretty
close.'' [Tr. 120]. He also reiterated that Dr. Reitman is ``on the
road to recovery, if not completely recovered,'' and he does not
foresee him relapsing. [Tr. 122].
56. Dr. Colaprete stated that Dr. Reitman ``loves his patients,''
is ``very conscientious,'' and was a ``very professional physician.''
[Tr. 122]. At no point did Dr. Colaprete ever note any strange behavior
on the part of Dr. Reitman. [Tr. 123-24].
3. Dr. William Friedel
57. Dr. William Friedel is a graduate of Brown University. He
attended Albert Einstein College of Medicine, interned at Downstate in
Brooklyn, New York, and returned to Albert Einstein for his residency
in urology. He has been a practicing urologist in California since
1973. [Tr. 127].
58. Dr. Friedel has known Dr. Reitman as a friend and colleague for
over 35 years. [Tr. 126-27, 138-9]. They belong to a religious group.
They also worked together at El Cajon Valley Hospital. Dr. Friedel was
Dr. Reitman's patient until approximately six or seven years ago when,
after Dr. Friedel had a heart attack, he began seeing a cardiologist as
his primary physican. [Tr. 127-28].
59. Dr. Friedel stated that, ``as a sophisticated consumer of
medical care * * * I certainly would not have seen [Dr. Reitman] if I
did not think he was more than competent.'' [Tr. 129]. He also said
that his opinion of Dr. Reitman's medical abilities was ``excellent.''
[Tr. 129]. He has observed Dr. Reitman with patients. Dr. Friedel
testified that Dr. Reitman is an ``excellent physician'' who ``cares
about his patients and takes good care of them.'' [Tr. 134, 141].
During the 2002 to 2009 time frame, he did not suspect that Dr. Reitman
was interacting with patients while he was under the influence of a
controlled substance. [Tr. 141].
60. In July of 2009, Dr. Reitman told Dr. Friedel of his years of
self-prescribing of controlled substances. [Tr. 129, 139]. Dr. Friedel
advised Dr. Reitman to meet with Grossmont Hospital's Wellness
Committee. [Tr. 130]. Dr. Friedel has been a member of this committee
for over 20 years. [Tr. 130-31, 135]. Though he admits he is not an
addictologist, he states that from a practical point of view, he is
very experienced in addiction issues. [Tr. 131, 135].
[[Page 60895]]
61. Dr. Reitman has since met with the committee and will continue
to meet with the committee regularly. [Tr. 132, 136]. However, Dr.
Friedel stated that the committee does not really ``monitor''
physicians, but rather has the doctors come in and talk with the
committee periodically. The committee also assigns a mentor to keep in
close contact with the physicians. He is unsure if the committee has
appointed a mentor for the Respondent. [Tr. 135-36].
62. Dr. Friedel stated that Dr. Reitman has ``an excellent chance
of not abusing codeine in the future. It's crystal-ball-gazing, as you
know. There's a certain relapse rate for people who use drugs. I think
* * * it's unlikely that he would do that.'' [Tr. 133]. He added that
Dr. Reitman ``absolutely'' appears committed to recovery. [Id.]. He
knows that Dr. Reitman abused controlled substances for several years
and that he has only been free of controlled substances for nine
months. [Tr. 136]. He could not say that Dr. Reitman is recovered, but
used the more general term of ``recovering.'' He compared it to being
cured, stating that ``[y]ou only know somebody's cured when they die
and they don't have it anymore.'' He later added, ``It's like the
alcoholic describing themselves as [a] non-drinking alcoholic.'' [Tr.
136-37, 140].
63. Dr. Friedel stated that the committee only sees about one, new
physician with substance abuse problems every three years. [Tr. 137].
He has seen physicians relapse even when they seemed committed to
recovery. [Tr. 137].
64. When asked, with regards to a physician who is addicted to
controlled substances, whether access to controlled substances would be
conducive to recovery, Dr. Friedel said: ``There's no doubt that
anybody who has free access to drugs is more likely to abuse drugs, and
probably the best example I can use is an anesthesiologist who, as a
profession, are more likely to become addicted, because the drugs are
poorly accounted for and readily available. With that analogy, of
course, anybody who has more access to drugs is probably more likely to
abuse that access. On the other hand, I think Dr. Reitman's very
committed not to do this.'' [Tr. 138].
65. Dr. Friedel stated that Dr. Milner was ``the guy in addiction
medicine * * * he's the guy to go to.'' [Tr. 134].
4. Rabbi Avram Bogopulsky
66. Rabbi Avram Bogopulsky did his initial training in Muncie, New
York under the tutelage of Rabbi Wein for eight years, encompassing
detailed study, Talmudic study, rabbinical study, and pastoral care. He
then served as an assistant rabbi in Charleston, South Carolina for
three years. Now he has led the Beth Jacob Congregation in San Diego
for the past 14 years. [Tr. 144].
67. Dr. Reitman has attended Beth Jacob for 14 years. [Tr. 144].
Rabbi Bogopulsky considers him ``one of our better congregants as far
as he attends daily minion, which is a gathering of a quorum of ten * *
* every single morning.'' [Tr. 144]. They talk on a regular basis. [Tr.
145, 148-9]. Dr. Reitman is one of two vice presidents of the
congregation. [Tr. 145].
68. Rabbi Bogopulsky, his wife, and his son are all patients of Dr.
Reitman. [Tr. 145]. Rabbi Bogopulsky stated that Dr. Reitman is a
``very good doctor.'' [Tr. 146].
69. In July of 2009, Dr. Reitman came to Rabbi Bogopulsky for
spiritual guidance related to his years of addiction and self-
prescribing of controlled substances. [Tr. 146-7]. Rabbi Bogopulsky
stated that this came as a shock, because the Respondent never appeared
to be under the influence. [Tr. 148]. He stated that Dr. Reitman ``has
an impeccable character with a deep concern for people * * * and is a
role model in the community.'' [Tr. 149].
70. Rabbi Bogopulsky testified that Dr. Reitman showed remorse and
was ``absolutely regretful.'' [Tr. 150]. He also stated that Dr.
Reitman has ``demonstrated to this day, every single day, a
commitment'' to recovery. [Id.]. He explained that, in Orthodox
Judaism, the Sabbath is a day of holiness. On the Sabbath, ``we do not
use electricity, we don't answer the phone, drive, computers.''
However, part of the recovery process requires Dr. Reitman to call in
on a daily basis. Therefore, he and Rabbi Bogopulsky have an agreement
where Rabbi Bogopulsky allows Dr. Reitman to essentially bypass Jewish
law and use Rabbi Bogopulsky's office phone to call in on the Sabbath.
[Tr. 150-51]. Rabbi Bogopulsky stated that this allows him to maintain
his religious faith and still carry out his commitment to recovery.
[Tr. 151].
71. Rabbi Bogopulsky also said that he never suspected Dr. Reitman
of abusing drugs and that he had no inclination that he was under the
influence of any drugs. [Tr. 152]. He admitted that he is neither a
medical doctor nor an addiction specialist. However, he testified that
in his position as a spiritual leader, he has counseled people with
addiction problems before, but he typically finds a more qualified
counselor to help addicts. [Tr. 152-3].
5. Dr. John E. Milner
72. Dr. John E. Milner graduated from the University of Texas
Medical School in Dallas in 1957. He interned at the Naval Hospital in
Camp Pendleton and served as a general duty medical officer until 1961.
He was in private practice in La Jolla, California from 1961-66. He
began psychiatric training in 1966, eventually completing a child and
adolescent fellowship in psychiatry in 1970. In the mid-1970s, he
opened an alcohol and drug treatment unit in San Diego, California
called Sharp Cabrillo Hospital. He received a certificate in addiction
medicine in 1986. He also opened a non-hospital-based treatment program
for alcohol or drug dual diagnosis patients called Rancho L'Abri. He
has been the medical director at Rancho L'Abri for more than 25 years.
He indicated that he has probably treated thousands of patients and
hundreds of physicians with drug and alcohol issues. [Resp. Exh. 10;
Tr. 181-4, 190].
73. Dr. Reitman came to Rancho L'Abri as an inpatient on August 3,
2009. [Resp. Exh. 1; Tr. 184-5]. Dr. Milner's team, under his
direction, created a treatment plan for Dr. Reitman. [Resp. Exh. 2; Tr.
186-7]. In addition, the team also maintains patient progress notes,
which are reviewed by Dr. Milner. [Resp. Exh. 3; Tr. 187-8]. The team
also conducts urine toxicology screening and keeps records of the
results. [Resp. Exh. 4; Tr. 189]. When Dr. Reitman arrived at Rancho
L'Abri, his urinalysis results showed him as negative for both opioids
and barbituates. [Resp. Exh. 4; Tr. 203]. Dr. Reitman continues to
receive urine screens. [Tr. 204].
74. Dr. Milner diagnosed Dr. Reitman with opioid addiction. He did
not diagnose Dr. Reitman with barbiturate addiction. He did not know
that Dr. Reitman ordered four times as much Butalbital as he did APAP
with codeine. [Tr. 200]. Dr. Milner said that Butalbital is a very mild
sedative that can cause a person to become ``sort of intoxicated'' in
huge doses. [Tr. 201]. He testified that he never saw any barbiturate
withdrawal symptoms, and ``a person who's severely addicted is going to
manifest them.'' [Tr. 201].
75. By July 2009, Dr. Reitman was taking approximately 660 mg of
codeine per day. [Tr. 190-91, 202]. Dr. Milner stated that codeine is
very kind on the human brain, ``so it's very, very likely, conceivable,
and totally possible that he can function * * * as normally as he did
with this dose of codeine in him.'' [Resp. Exh. 6; Tr. 192]. He said
that his team looked extensively for any
[[Page 60896]]
evidence that Dr. Reitman failed to function as a physician during the
period that he was abusing codeine, but could find no such evidence.
[Tr. 192].
76. Dr. Milner testified that Dr. Reitman arrived at Rancho L'Abri
having already stopped taking codeine. ``He was deeply ashamed,
humiliated, aghast that he had been doing this for so long.'' [Resp.
Exh. 3 at 1-4; Tr. 192-93].
77. Dr. Milner said that Dr. Reitman has been committed ``since the
very beginning'' to stop using the drugs. [Tr. 193]. To the best of his
extensive knowledge, he stated that Dr. Reitman has ``rigorously
attended all the recommended behaviors and attitudes and processes.''
[Tr. 193-4]. When asked to rate Dr. Reitman's commitment to recovery on
a scale of one to ten, Dr. Milner said, ``Nine. Ten. Yeah, he's
committed.'' [Tr. 194]. He also stated that ``as long as he continues
the process he's involved in, the risks [of relapse] are minimal.''
[Tr. 194]. Dr. Milner believed that it would be in the interest of the
public to continue to allow Dr. Reitman to prescribe controlled
substances, and he would expect the urine monitoring and continued
involvement in his own recovery plan to continue. [Tr. 195-96].
Admitting that it is possible for a person who has demonstrated their
commitment to recovery to relapse, Dr. Milner asserted that as long as
the individual continues to be monitored and continues to follow
recommended processes, the chances of relapse are very slim. [Tr. 196-
97]. Dr. Milner knew that Dr. Reitman had abused for several years and
had only been clean for approximately nine months. [Tr. 198]. He also
stated that the chance of relapse in the earlier period of recovery is
increased. [Tr. 199].
78. Dr. Milner testified that if a physician is in the proper
monitoring program, then access to ``one's drug of choice'' would not
be harmful. [Tr. 199].
79. Dr. Reitman's wife was continuously supportive throughout Dr.
Reitman's stay at Rancho L'Abri, providing Dr. Reitman with kosher
meals and attending family sessions. [Resp. Exh. 3 at 1-4, 6-7].
6. Dr. Sandra Jassmann
80. Dr. Sandra Jassmann received a medical degree from Medical
College of Virginia in 1969. She had three years of internal medicine
at Cleveland Clinic in Cleveland, Ohio from 1969 to 1972. She served
two years with the United States Navy in Charleston, South Carolina
from 1972 to 1974. Then, from July 1, 1974, to June 10, 1976, she
participated in a fellowship in endocrinology at Sepulveda VA in
Sepulveda, California, an affiliate of UCLA. She began working in San
Diego in 1976. [Tr. 207].
81. Dr. Jassmann met Dr. Reitman in 1976 and worked closely with
him for 30 years. [Tr. 208]. She considers Dr. Reitman to be a ``very
competent, very capable, very professional'' doctor who has ``the
interests of his patients at heart.'' [Tr. 208-9, 212].
82. In August of 2009, Dr. Reitman told Dr. Jassmann that he had an
addiction problem and would be going into rehab. [Tr. 209]. Dr.
Jassmann stated that she was ``astounded, [] had no way of knowing,
[and] had not observed anything.'' [Tr. 210]. He was ``never''
lethargic, loopy, or seemed to be under the influence of any medication
during the period from 2002 through 2009. [Id.]. She had never heard
any complaints about Dr. Reitman. [Tr. 211, 212]. Dr. Jassman was aware
of the 2002 action by the California Medical Board. However, she stated
that this does not change her opinion of Dr. Reitman's abilities. [Tr.
212-3]. She no longer works with Dr. Reitman; however, Dr. Jassmann
testified that, if she did, she would allow him to cross-cover her
patients. [Tr. 213-4].
83. Dr. Jassmann stated that she felt confident that Dr. Reitman is
able to conduct his practice successfully with regards to patients and
prescribing. [Tr. 211]. She said that he was an excellent practitioner
of internal and geriatric medicine. [Tr. 212].
84. Dr. Jassman testified that Dr. Reitman was remorseful about the
fact that he had abused codeine. [Tr. 211].
7. Philip Shapiro, Esq.
85. Philip Shapiro is an attorney in San Diego. He went to college
at Southern Illinois for his undergraduate degree. Then, he attended
San Diego State for his Master's. For his J.D., he attended Thomas
Jefferson School of Law. Prior to becoming an attorney, he served as a
special agent with the United States Secret Service. [Tr. 216-17].
86. Mr. Shapiro had been addicted to cocaine. He is currently
involved in Alcoholics Anonymous. He has been recovering for a total of
11 years. He has sponsored five people and is currently Dr. Reitman's
sponsor. [Tr. 217]. Dr. Reitman is currently undergoing the twelve-step
program, and is on step four. He is unsure, but he believes that Dr.
Reitman has also completed the 90 in 90 program. Dr. Reitman and Mr.
Shapiro had been talking every day, but now they talk three to four
times per week on the phone, and 90% of the time, they meet in person
on Sundays. [Tr. 218-19, 221].
87. With regards to Dr. Reitman's commitment to recovery, Mr.
Shapiro said, ``I honestly would say that I think [Dr. Reitman] has the
greatest chance of any person I've ever sponsored.'' [Tr. 219].
However, he also stated that he has seen other AA members relapse, even
those that were remorseful about their past addiction and abuse. But,
if the addicted person comes to meetings and doesn't abuse between
meetings, then ``he or she will make it.'' [Tr. 222]. Also, having easy
access to one's drug of choice can make it much tougher to stay sober.
[Tr. 223]. Mr. Shapiro has seen individuals with 22 years of sobriety
relapse. He stated that it is the individual's level of commitment to
sobriety that seems to determine whether or not they are going to
relapse. [Tr. 223-24].
88. Mr. Shapiro said that Dr. Reitman has been very open about his
problem from the beginning. [Tr. 219]. He does not blame anyone but
himself. [Tr. 220].
89. Mr. Shapiro testified that he would feel comfortable going to
Dr. Reitman as his personal physician. In fact, he sent his daughter to
Dr. Reitman. [Tr. 220].
8. Christine Kuwazaki
90. Christine Kuwazaki has known Dr. Reitman for 26 years. She is
his back office assistant and his practice manager, doing billings,
claims and charges. She works closely with Dr. Reitman on a daily
basis. [Tr. 226-27, 233].
91. Ms. Kuwazaki stated that Dr. Reitman is ``very caring, very
ethical, and conscientious with patient care.'' [Tr. 228, 231, 235].
92. However, she did not know that he was using his DEA
Registration to order controlled substances for personal use. [Tr.
235].
93. To her knowledge, Dr. Reitman does no dispensing at his
practice. No pharmacy representatives leave samples at the practice.
[Tr. 236].
94. From the period of 2002 through the present, Dr. Reitman has
only had a couple of patient complaints. [Resp. Exh. 9 at 2; Tr. 228].
She described them as ``typical.'' [Tr. 234].
95. Dr. Reitman told Ms. Kuwazaki that he had been abusing codeine
on July 8, 2009. Up until that point, she did not see any evidence of
him being under the influence of drugs. [Tr. 229-30]. He told her that
he was going into rehab. She helped him reschedule patients during this
time. [Tr. 230].
96. Prior to that time, she did not know that, at his office, he
stored the drugs he self-prescribed. [Tr. 234].
97. Ms. Kuwazaki knew that Dr. Reitman had a problem with
headaches.
[[Page 60897]]
She could tell when he had a ``really bad'' headache, because he looked
ill and would have to go home for the day. [Tr. 230-31]. Now that Dr.
Reitman has completed rehabilitation, Ms. Kuwazaki stated that he looks
relieved and focused. [Tr. 231].
98. Ms. Kuwazaki does not think that his ability to write
controlled substance prescriptions would be a problem for Dr. Reitman.
[Tr. 232]. Ms. Kuwazaki stated that she would trust him to be her own
personal doctor. [Tr. 232-3].
E. Medical Board of California
99. On March 17, 2010, the Medical Board of California (``Board'')
filed an accusation against Dr. Reitman for ``self administering a
dangerous drug,'' ``violation of drug statutes and regulations,'' and
``general unprofessional conduct.'' [Govt. Exh. 6]. However, the Record
contains no evidence that the Board has conducted a hearing or imposed
any restrictions on the Respondent's medical license.
IV. Conclusions of Law and Discussion
A. Position of the Parties
1. The Government
The Government asserts that the Respondent's continued registration
is inconsistent with the public interest. [Government's Proposed
Findings of Fact and Conclusions of Law (``Govt. Brief'') at 10].
First, the Government states that the Medical Board of California
has filed an accusation against the Respondent. [Govt. Brief at 5].
While admitting that no final action has been taken on the accusation,
the Government avers that the sanction being sought is revocation or
suspension of his medical license. The Government concludes that this
action, nonetheless, ``reflects the Board's recommendation as to
Respondent's continued ability to practice medicine in the State of
California.'' [Govt. Brief at 5-6].
Next, the Government contends that the Respondent's behavior was
``not an isolated incident of misuse, but was a continued pattern of
behavior that continued over a seven year period.'' [Govt. Brief at 6].
Further, the Government notes that Respondent ``was not compliant with
Federal law or the laws of the State of California.'' [Id.]. The
Government asserts that the Respondent was indeed a dispenser, because
he dispensed to himself, and is thus subject to Federal recordkeeping
requirements, with which he did not comply. [Govt. Brief at 6-7].
Respondent's actions in self-prescribing and administering controlled
substances also violated California law. [Govt. Brief at 7-8]. The
Government contends that these violations ``weigh in favor of finding
that Respondent's continued registration would be inconsistent with the
public interest.''
Third, the Government notes that the Respondent was initially
prescribed the controlled substances he later ordered for his own
abuse. According to the Government, this does not negate the fact of
his misdeeds. [Govt. Brief at 8]. The Respondent exploited his
controlled substances registration and did not ask his physician to
continue prescribing, because he knew that his intake of controlled
substances was a problem. [Govt. Brief at 8-9].
The Government goes on to argue that though it appears Respondent's
addiction never adversely affected his practice, Respondent was merely
able to hide his addiction from everyone around him for seven years.
[Govt. Brief at 9]. According to the Government, this exemplifies his
ability to conceal future abuse. [Id.].
The Government next notes that, though the Respondent voluntarily
entered a variety of rehabilitative efforts, ``which no doubt
demonstrates a commitment to staying clean and sober * * * he has only
been sober for a period of approximately eleven months. He abused
controlled substances for a period of seven years.'' [Id.].
Additionally, the Government notes the chances that the Respondent will
relapse could be enhanced, because he is in the ``early stages of
recovery,'' and because, if he is permitted to retain his registration,
he would have access to controlled substances. [Govt. Brief at 9-10].
In conclusion, the Government states that it ``has met its burden
in proving that the Respondent's continued registration is inconsistent
with the public interest.'' [Govt. Brief at 10]. Therefore, Dr.
Reitman's registration should either be revoked or, alternatively,
suspended for one year and subject to conditions for three years upon
reinstatement. [Govt. Brief at 10-11].
2. The Respondent
The Respondent argues that his continued registration is not
``inconsistent with the public interest'' pursuant to 21 U.S.C. 824(a).
[Respondent's Post-Hearing Proposed Findings of Fact, Conclusions of
Law, and Argument (``Resp. Brief'') at 1].
The Respondent notes that Dr. Reitman has been subjected to no
adverse recommendation by the state licensing board and also has no
convictions under Federal or State laws. [Resp. Brief at 12, 13]. The
Respondent further adds that Dr. Reitman is experienced in handling
controlled substances and, ``exclusive of the subject at issue in this
case, Dr. Reitman has been responsible in his distribution of
controlled substances and compliant with DEA laws.'' [Resp. Brief at
13].
The Respondent next avers that, despite his own self-prescribing,
his practice during this time period does not indicate that he placed
the public at risk. [Resp. Brief at 13-15]. He cites one DEA hearing
where a physician was ultimately found guilty of felonious self-
prescribing by subterfuge in a manner the Respondent considers more
egregious than his own conduct. Mary Thomson, M.D., Continuation of
Registration With Restrictions, 65 FR 75,969, 75,970 (DEA 2000); [Resp.
Brief at 14]. He also notes that one similarity between the two cases
is that both doctors harmed no one but themselves. [Resp. Brief at 15].
Therefore, the Respondent argues that since his conduct was not as
shocking as the actions taken by Dr. Thomson, Dr. Reitman should also
be permitted to continue his registration with restrictions. [Resp.
Brief at 14-15].
The Respondent also states that ``patient care was not affected
during the time frame that Dr. Reitman was abusing codeine.'' [Resp.
Brief at 15-16].
The Respondent then points out that he has fully accepted
responsibility for his actions and has minimal risk of relapsing.
[Resp. Brief at 16-17]. He cites two DEA cases for the proposition that
``the paramount issue is not how much time has elapsed since (the
Respondent's) unlawful conduct, but rather, whether during that time
(the) Respondent has learned from his past mistakes and has
demonstrated that he would handle controlled substances properly if
entrusted with [a] DEA registration.'' John Porter Richard, D.O., 61 FR
13,878 (DEA 1996); Leonardo v. Lopez